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1. ABSTRACT 
 
Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing 
and mitochondrial pathways. 
 
Myotonic Dystrophy type 2 (DM2) is caused by a DNA microsatellite expansion within the ZNF9 
gene leading to an abnormal splicing pattern largely responsible for the pathological condition. To 
better define the functional changes occurring in human DM2 myotubes, we performed a 
quantitative proteome comparison between myotubes of DM2 and control patients using two-
dimensional gel electrophoresis followed by mass spectrometry. Our results indicate that the 
proteins, altered in DM2 cultures, belong to two major functional categories: i) mitochondrial 
components, with a reduction of Elongation factor Tu (EFTu), Heat Shock Protein 60 (HSP60), 
Glucose Regulated Protein 75 (GRP75) and Dienoyl-CoA-Isomerase, an enzyme involved in fatty 
acids degradation; ii) the ubiquitin proteasome system, with increase of the 26S proteasome 
regulatory subunit 13 and a reduction of Proteasome subunit Apha 6 and of Rad23B homolog. 
Altered ubiquitin-proteasomal activity is supported by a global reduction of cytosolic ubiquitinated 
proteins, nonetheless the accumulation of ubiquitin-protein conjugates after proteasomal inhibitor 
MG-132 treatment is maintained in DM2 and control cells, suggesting a higher degradation rate for 
the proteasome in myoblasts from patients affected by the disease. Although future work is required 
to clarify how these changes affect the protein degradation machinery and mitochondrial function 
and to evaluate if these changes also occur in the biopsies of DM2 patients, these results identify the 
mitochondrial proteins and the ubiquitin-proteasomal system as candidates potentially relevant to 
DM2 pathogenesis. Further analysis performed in Human skin fibroblasts primary cultures, 
obtained from patients biopsies, revealed an Hyperpolaryzation of the mitochondrial membrane 
potential involving DM2 cells, indicating a putative functional issue for mitochondria. As the 
evaluation of the Cytocrome c release following hydrogen peroxide treatment showed a differential 
response to this stress inducing compound, we pointed out a functional involvement of the DM2 
mitochondrial-mediated cellular response to oxidative stress. 
Keywords: 
Myotonic Dystrophy; Proteomics; Myotubes, Mitochondria, Ubiquitin-Proteasome System, 
Ubiquitination, Protein Folding, Protein Disulfide Isomerase, Chaperone Proteins. 
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20-)0+,#( J/I*#-8( F+$.( J/I*#-( $#( "'%*( 5( 20-)0+,#( J/I*#-( ,+-$( #*J*##*4( "$( ,-( #*4( J/I*#-`( ,#*(
),%,I+*($J(-+$.(I0"(%#$"#,)"*4()$3"#,)"/$3-()$2%,#*4("$(J,-"(J/I*#-`(,34(#*+'(0%$3("&*(,*#$I/)(
2*",I$+/-2`("&,"(/-("&*(0-*($J("&*(2/"$)&$34#/,+(%#$40)*4(!=G8(
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Figure. 2 (www.neuropathologyweb.org/chapter13/chapter13cDystrophy.html) One of the foundamental characteristic 
of the DM patient’s muscle fibers are the centralized nuclei which normally can be found only at the periphery of 
muscle cells. The letter R, in white, marks a reduced-diameter fiber. 
R,-"(J/I*#-(),3()$3"#,)"(J,-"*#`(I0"(J$#(,(+/2/"*4(/3"*#;,+($J("/2*`(,34("&*'(,#*(,+-$(#*J*##*4("$(
,-( .&/"*`( "'%*( ".$( J/I*#-8( =&*'( 2,/3+'( 0-*( "&*( ,3,*#$I/)( 2*",I$+/-2( #*+'/31( 0%$3( "&*(
1+/)$+'-/-L(%#$40)*4(!=G8(@"(/-(.$#"&(3$"/31("&,"("&*(V=M(,34("&*(VV=M(#*%*,"-(,2%+/J/),"/$3-(
K#*-%*)"/;*+'( /3(C:5( ,34(C:7N( ,#*( %#*-*3"( $3( I$"&(20-)0+,#( J/I*#( ^/34-KZ,--*Q( *"( ,+8( 7\\TN8( =$(
)$3)+04*( "&*( -'2%"$2-(4/--*#","/$3(.*(./-&( "$( -%*34( -$2*(.$#4-(,I$0"( "&*( b!3"/)/%,"/$3(
%&*3$2*3$3ca( )&/+4#*3($J(C:5(%,"/*3"-( "*34( "$(4*;*+$%( "&*(%,"&$+$1'( *,#+/*#( ,34( /3(2$#*(
-*;*#*(J$#2()$2%,#*4("$("&*/#(%,#*3"-`("&/-(/-(40*("$("&*(1*3*"/)(/3-",I/+/"'($J("&*(V=M(#*%*,"-(
,2%+/J/),"/$3`(,34("&*(302I*#($J(#*%*,"-(%#$1#*--/;*+'(1#$.-(/3("&*(-0))**4/31(1*3*#,"/$3-8(
!J"*#( -$2*(1*3*#,"/$3-(C:5(%,"/*3"-( ),3(4*;*+$%( "&*(2$-"( -*;*#*( J$#2($J( "&*(C:5`( "&*( -$(
),++*4( V$31*3/",+( :'$"$3/)( C'-"#$%&'`( ,--$)/,"*4( "$( ,3( *O"#*2*+'( +$31( V=M( ,2%+/J/),"/$38(
C/JJ*#*3"+'( J#$2( C:5`( "&*( VV=M( #*%*,"-( ,2%+/J/),"/$3( 034*#+'/31( "&*( C:7`( "*34-( "$( 1#$.(
40#/31("&*(+/J*(-%,3($J("&*(%,"/*3"8(Z'(,3,+'Q/31("&*(I+$$4(-,2%+*-`(/"(.,-(%$--/I+*("$(*-",I+/-&(
,( )$##*+,"/$3( I*".**3( "&*( ,1*( $J( "&*( %,"/*3"( ,34( "&*( 302I*#( $J( VV=M( #*%*,"-8( =&/-(
%&*3$2*3$3(.,-(3,2*4(=*"#,%+*"( >O%,3-/$3( @3-",I/+/"'KC,'( *"( ,+8( 7\\<N8( !( J0#"&*#(%#$$J( $J( "&*(
"*"#,%+*"(/3-",I/+/"'(),2*(J$#2("&*(%$-/"/;*()$##*+,"/$3(I*".**3("&*(,2%+/J/),"/$3(+*31"&(,34(
"&*(,1*($J($3-*"($J("&*(C:7(%,"&$+$1'8(
(
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(
78<(:$+*)0+,#(:*)&,3/-2(
=&*(%,"&$1*3*"/)(&'%$"&*-/-(/-(I,-*4($3(,(2*)&,3/-2(),++*4(b=$O/)(M,/3($J(R03)"/$3(:$4*+c8(
=&/-(2$4*+(/-(I,-*4($3("&*(,))020+,"/$3($J("&*(%#*L2?B!-(),##/31("&*(V=M(KC:G](?B!N(,34(
VV=M( ,2%+/J/),"/$3-( KJ/#-"( /3"#$3( -%+/)*4( $J( e3JXN`( #,/-/31( "&*( J$#2,"/$3( $J( #/I$30)+*,#(
,2%+/J/),"/$3-(),++*4(bR$)/c(K:,3^$4/(*"(,+8(7\\<N8(
(
(
(
(
(
(
(
R/10#*8(<(KGB!F((B$;*2I*#(5H`(7\\H(((;$+8(5\7((3$8(69((59979L599<5N8(K!`ZN(F*)$34,#'(V=M(#*%*,"-(-"#0)"0#*(,34(
4$0I+*(-"#,34(J$#2,"/$38(KVN(=.$(40$I+*(&*+/)*-(,#*(-"/)^/31(*,)&($"&*#(-&$./31("&*(/3/"/,+(R$)/(J$#2,"/$3(*;*3"(
KCN(=&#**L4/2*3-/$3,+(%#*4/)"/$3($J("&*(?/I$30)+*,#(@3)+0-/$3-8(
!"("&*(+*;*+($J("&*(R$)/`("&*(20","*4(?B!(,)f0/#*-(,(-*)$34,#'(-"#0)"0#*`(/3(%,#"/)0+,#(&,/#%/3(
-"#0)"0#*-`( ,34( ,11#*1,"*-( #*,)&/31( )$3-/4*#,I+*( 4/2*3-/$3-KB,%/*#,+,( *"( ,+8( 5XXSN8( >;*3( /J( "&*(
I/34/31( I*".**3( "&*( #*%*,"-( ,"( "&*( +*;*+( $J( "&*( -"*2`( -&$.-( ,( WLW( 2/-2,")&`( "&*( &,/#%/3(
-"#0)"0#*( /-( ;*#'( -",I+*( ,34( )+$-*( "$( 5\\i( )$2%+*2*3",#/"'`( ,3'.,'( "&*( %#*-*3)*( $J(
2/-2,")&( )$0+4( "#/11*#( ,( %*#/$4/)( ,+"*#,"/$3( $J( "&*( -0#J,)*( *+*)"#$-","/)( %$"*3"/,+( ,I+*( "$(
-"#*31&"*3("&*(/3"*#,)"/$3-(I*".**3("&/-(-"#0)"0#*(,34("&*(?B!(I/34/31(%#$"*/3-(-*f0*-"*#*4(
,"( "&*( +*;*+( $J( "&*( R$)/8( =.$( )+,--*-( $J( ?B!( I/34/31( %#$"*/3-`( #*J*##*4( "$( ,-( F%+/)/31(
?*10+,"$#-`( -**2( "$( %+,'( ,( %/;$",+( #$+*( /3( "&*( %,"&$1*3*-/-( $J( "&*( 4/-*,-*`( I'( ;/#"0*( $J( "&*(
-*f0*-"#,"/$3($J($3*($J(/"(/3-/4*("&*(R$)/a("&*(:0-)+*I+/34(5L+/^*(J,2/+'(K:ZBA-N(,34("&*(VWML
I/34/31(%#$"*/3`($#(>=?<L+/^*(J,2/+'(KV>ARN($J(-%+/)/31(#*10+,"$#-`(/3(%,#"/)0+,#(VWMZG58(=&*(
:0-)+*I+/34( J,2/+'( $J( %#$"*/3-( %+,'-( ,3( /2%$#",3"( #$+*( /3( "&*( ,+"*#3,"/;*( -%+/)/31( %#$)*--8(
!)"/;,"*4( ,J"*#( I/#"&`( /"( +*,4-( "$( "&*( *O)/-/$3( $J( J$*",+( *O$3-( ,34( "$( "&*( *O%#*--/$3( $J( "&*(
,%%#$%#/,"*(/-$J$#2-(/3-"*,4($J("&*(J$*",+($3*-(KD$(*"(,+8(7\\6N8((
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(
R/10#*8( 6( KU( B*0#$+( B*0#$-0#1( G-')&/,"#'( 7\5\jT5a<HTL<9S( 4$/a5\855<9Pg33%87\\T85HT795N8( F)&*2,"/)(
#*%#*-*3","/$3( $J( "&*( 2*)&,3/-2( $J( "&*( C:( %,"&$+$1'`( -&$./31( "&*( /2%,/#2*3"( $J( "&*( -%+/)/31( #*10+,"$#(
*f0/+/I#/02( 40*( "$( R$)/( -*f0*-"#,"/$3( $J( :ZBAL5( %#$"*/3`( ,34( "&*( %,"&$+$1/)( -%+/)/31( %,""*#3( /3;$+;/31(
/2%$#",3"(1*3*-8(
=&/-( J,2/+'( $J( %#$"*/3-( .,-( J/#-"( 4/-)$;*#*4( /3( C#$-$%&/+,`( .&*#*( /-( #*-%$3-/I+*( J$#( "&*(
"*#2/3,+(4*;*+$%2*3"($J( "&*(%&$"$#*)*%"$#-(,"( "&*( +*;*+($J( "&*( /3-*)"(*'*-`(,34( +*,4-( "$( "&*(
)$##*)"(4*;*+$%2*3"($J("&*(F^*+*",+(20-)+*(,%%,#,"0-K!#"*#$(*"(,+8(5XXTN8(W%("$(3$.("&#**(/-$J$#2-(
$J( :0-)+*I+/34( &,;*( I**3( 4/-)$;*#*4( /3( :,22,+-a( :0-)+*I+/34L+/^*( 5( K:ZBA5( $#( :ZBAN`(
:0-)+*I+/34L+/^*( 7( K:ZBA7($#(:ZAAN( ,34(:0-)+*I+/34L+/^*( <( K:ZBA<($#(:Z_AN8(Y&/+*( "&*(
J/#-"(".$(/-$J$#2-(,#*(2,/3+'(*O%#*--*4(/3("&*(F^*+*",+(20-)+*-`("&*("&/#4($3*(/-(*O%#*--*4(/3(
"&*(G+,)*3",K:/++*#( *"( ,+8( 7\\\N8(=&*(V>AR( J,2/+'($J( -%+/)/31( #*10+,"$#-`( ,34( /3(%,#"/)0+,#(VWMZG5(
,)"-( /3( ,3( ,3",1$3/-"/)( J,-&/$3(./"&( #*-%*)"( "$(:ZBAL5`( %#$2$"/31( "&*( /3)+0-/$3-( $J( J$*",+(
*O$3-(/3(%,#"/)0+,#(2?B!-(40#/31("&*(%#*L?B!(2,"0#,"/$38(=&/-(".$(,3",1$3/-"/)(%#$"*/3-(4$(
3$"()$2%*"*(4/#*)"+'(./"&(*,)&($"&*#`(-/3)*("&*'(#*)$13/Q*(4/JJ*#*3"()$3-*3-0-(-*f0*3)*-(,"(
"&*( +*;*+( $J( "&*( "#,3-)#/%"-( KC,3-$"&$31( *"( ,+8( 7\\HN8( VWMZG5`( 4/JJ*#*3"+'( J#$2( :ZBA5( 4$*-( 3$"(
)$+$),+/Q*( ./"&/3( "&*( J$)/`( I0"( /-( $;*#*O%#*--*4( /3( 2'$I+,-"( )*++( )0+"0#*-( ,34( 20-)0+,#(
I/$%-/*-( J#$2(C:5( %,"/*3"-8( =&/-( /-( ,(2$+*)0+,#( -/13,"0#*( $J( "&*( C:K=/2)&*3^$( *"( ,+8( 7\\5N8( =&*(
:0-)+*I+/34(5(,34(7(-*f0*-"#,"/$3(,"("&*(+*;*+($J("&*(#/I$30)+*,#(/3)+0-/$3-`(,34("&*(VWMZG5(
$;*#*O%#*--/$3(-**2("$(I*("&*(2,/3(#*,-$3-(J$#("&*(,I3$#2,+/"/*-($J("&*(-%+/)/31(%#$)*--*-($J(
,( 302I*#( $J( 1*3*-( .&/)&( ),3( I*( ,--$)/,"*4( "$( "&*( )+/3/),+( 2,3/J*-","/$3-( $J( "&*( :'$"$3/)(
C'-"#$%&'8(W%("$(^3$.(77(1*3*-(/3)$##*)"+'(-%+/)*4(&,;*(I**3(#*)$13/Q*4(,"("&*(+*;*+($J(C:(
%,"/*3"-( -^*+*",+( ,34( ),#4/,)( 20-)+*-8( =&*-*( 1*3*-( %+,'( ,( #$+*( /3( "&*( 20+"/-'-"*2/)(
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-'2%$2,"$+$1'($J( ( "&*(4/-*,-*a(,2$31("&*($"&*#(:'$"$3/,`("#/11*#*4(I'(,3(,+"*#,"/$3($J("&*(
-%+/)/31( %#$)*--( $J( "&*( V&+$#/4*( V&,33*+( 5( KV+VB5N( ?B!K:,3^$4/( *"( ,+87\\7Nj( @3-0+/3( ?*-/-",3)*`(
),0-*4( I'( ,( 4/-*f0/+/I#/02( I*".**3( "&*( @?L!( ,34( @?LZ( ( -%+/)/31( /-$J$#2-( $J( "&*( @3-0+/3(
?*)*%"$#( K@?N( /3( .&/)&( *O$3( 55( /-( -^/%%*4( KF,;^0#( *"( ,+8( 7\\6Nj( "&*( D*,#"( !##'"&2/,-`( %#$I,I+'(
)$##*+,"*4(./"&("&*(*2I#/$3,+(-%+/)/31L/-$J$#2(%#*;,+*3)*($J("&*(V,#4/,)(=#$%$3/3(=(2?B!`(
"#,3-)#/I*4(J#$2("&*(=BB=7KG&/+/%-(*"(,+8(5XXTN8(
786(=#,3-1*3/)(2/)*(
@3($#4*#( "$(4*J/3*( "&*(%,"&$1*3*"/)(2*)&,3/-2-(034*#+'/31( "&*(:'$"$3/)(C'-"#$%&'(,34( "$(
)$##*+,"*("&*(2$+*)0+,#(I,-/-($J("&*(4/-*,-*(./"&("&*(20+"/-'-"*2/)(-'2%"$2,"$+$1'(,(302I*#(
$J( (1*3*"/),++'(2$4/J/*4(2/)*(&,-(I**3()#*,"*48( (Y/"&( "&*( /4*,( "$( "*-"( "&*(&'%$"*-/-( "&,"( "&*(
V=M(#*%*,"-(,2%+/J/),"/$3()$0+4(I*( #*-%$3-/I+*( /"-*+J( J$#( "&*(C:($3-*"`( ,(2/)*( /3(.&/)&( "&*(
V=M(,2%+/J/),"/$3(+/*-(/3(,(%$-/"/$3(./"&(3$()$##*+,"/$3("$("&*(C:G](1*3*(.,-(%#$40)*48(:/)*(
$J("&/-(^/34(&,;*("&*()&,#,)"*#/-"/)(7H\(V=M(20","/$3(,"("&*(+*;*+($J("&*(<dW=?($J("&*(F^*+*",+(
!)"/3( K:,3^$4/( *"( ,+8( 7\\\N8( =&*( #*-0+"-( 4*2$3-"#,"*4( "&,"( "&*( %,"&$+$1'( $#/1/3,"*-( J$++$./31( "&*(
*O%#*--/$3($J("&*("#,3-1*3/)(F^*+*",+(!)"/3(2?B!`(-0%%$#"/31("&*(,))0#,)'($J("&*(b=$O/)(?B!(
M,/3( $J( R03)"/$3b(2$4*+`( %#*4/),"/31( "&*( -0JJ/)/*3)'( $J( "&*( ,2%+/J/),"*4( V=M( #*%*,"-( */"&*#(
+$),+/Q*4(/3("&*(C:G](<dW=?($#(*;*#'.&*#*(*+-*`("$(1*3*#,"*(,(C:(%&*3$"'%*(/3(,1#**2*3"(
./"&( "&*( *O%#*--/$3( $J( "&,"( 1*3*( ,"( "&*( +*;*+( $J( "&*( -^*+*",+( 20-)+*-8( =&/-( 2$0-*( -&$.-(
,"#$%&'`()*3"#,+/Q*4(30)+*/`(-2,++(2'$J/I*#-`(,34(,(#*40)*4(.,+^/31(,34(#033/31(,I/+/"'(,"("&*(
?$",(?$,4("*-"`(-"#/)"+'(#/),%/"0+,"/31("&*(D02,3(C:5(%&*3$"'%*8(=$(*-",I+/-&(,(#$+*(J$#("&*(
:ZBA5(%#$"*/3(,34( "$(4*2$3-"#,"*( "&*(#*+,"/$3-&/%-(I*".**3("&*()+/3/),+(2,3/J*-","/$3-($J(
"&*(C:(,34("&*(-*f0*-"#,"/$3($J("&/-(%#$"*/3(,"("&*(+*;*+($J("&*("$O/)(#/I$30)+*,#(/3)+0-/$3-`(,(
:0-)+*I+/34( 5( ]E( 2$0-*( .,-( 1*3*#,"*4K],3,4/,( *"( ,+8( 7\\<N8( =&*( -^*+*",+( 20-)+*( -%+/)*$%,"&'(
,JJ*)"/31(:ZBA5( ]E(2/)*( /-( ;*#'( -/2/+,#`( /J( 3$"( /4*3"/),+`( "$( "&*( $3*( "#/11*#*4( I'( "&*( V=M(
#*%*,"-(,2%+/J/),"/$3(/3(D02,3`(,34(/3(V=ML7H\("#,3-1*3/)(2$0-*`(/3($"&*#(.$#4-`("&*(1*3*"/)(
-/+*3)/31( "$.,#4( :0-)+*I+/34L5( *;$^*-( )+/3/),+( J*,"0#*-( )&,#,)"*#/-"/)( $J( "&*( :'$"$3/)(
C'-"#$%&'a( F^*+*",+( :0-)+*-( ,+"*#,"/$3-`( V,",#,)"-`( ,+"*#3,"/;*( -%+/)/31( ,JJ*)"/$3( $J( "&*(
V&+$#/4*( V&,33*+L5`( ,34( "&*( )$3-*f0*3"( :'$"$3/,8( V$3-*f0*3)*-( $J( "&*( :ZBAL5( %#$"*/3(
/3,)"/;,"/$3(,#*(J0#"&*#(-0%%$#"*4(I'("&*(*;/4*3)*`($I",/3*4(/3("&*(2$0-*(2$4*+($J("&*(C:5`(
/3( .&/)&( "&*( V=M( ,2%+/J/),"/$3( +/*-( /3( "&*( <dW=?( $J( "&*( C:G]( 1*3*8( =&*( 20","/$3(
)$2%+*2*3","/$3($I",/3*4("&,3^-("$(,4*3$;/#,+(*)"$%/)(*O%#*--/$3($J("&*(:ZBAL5(%#$"*/3`(,"(
"&*( +*;*+( $J( "&*( -^*+*",+( 20-)+*-`( -*""+*-( 2'$"$3/,`( ,34( #*-"$#*-( "&*( -%+/)/31( %,""*#3(
,I3$#2,+/"/*-8( !40+"( /-$J$#2( $J( V+VBL5( #*%+,)*-( "&*( J$*",+( $3*`( ,34( "&*( *O%#*--/$3( $J( "&/-(
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V&+$#/4*( V&,33*+( ,"( "&*( +*;*+( $J( "&*( -,#)$2*#/)( 2*2I#,3*-( "0#3-( $0"( "$( I*( ,012*3"*4(
)$2%,#*4( "$( "&*( ,4*3$;/#,+( 03"#*,"*4( 2/)*8( !3'.,'`( 0+"#,-"#0)"0#,+( ,3,+'-/-( $J( "&*(
,4*3$;/#,+(/3J*)"*4(2/)*(#*;*,+*4(,I3$#2,+/"/*-(+/31*#/31($3(,"("&*(+*;*+($J("&*(20)+*(J/I*#-a(
)*3"#,+/Q*4(30)+*/( ,#*( -"/++( %#*-*3"`( ,-(.*++( ,-( "&*(VWMZG5($;*#*O%#*--/$3( ,34( "&*( ,"#$%&/)(
J*,"0#*-8( =&/-( *;/4*3)*( 4*2$3-"#,"*-( "&*( )$2%+*O/"'( $J( "&*( %,"&$1*3*-/-( $J( :'$"$3/)(
C'-"#$%&'`(-/3)*(/"(/-(3$"(%$--/I+*("$(4*J/3*(,(-/31+*(2*)&,3/-2(K+/^*("&*(/3,)"/;,"/$3($J(:ZBAL
5( %#$"*/3N( ,-( "&*( $3+'( )#/"/),+( *;*3"( +*,4/31( "$( "&*(2,3/J*-","/$3( $J( "&*( 4/-*,-*`( I0"( ,-( ,3(
/2%$#",3"(*;*3"()$3"#/I0"/31("$("&*(%,"&$1*3*"/)(%#$)*--8(=#,3-1*3/)(2/)*("&,"(#/),%/"0+,"*-(
*;*#'( D02,3( -'2%"$2( $J( "&*( C:5( &,;*( I**3( $I",/3*4( /3( "&*( +,I( $J( =&$2,-( V$$%*#(
KW3/;*#-/"'( $J( =*O,-( /3( C,++,-N( ,34( ,#*( )&,#,)"*#/Q*4( I'( "&*( %#*-*3)*( $J( ,( +$31( V=M(
,2%+/J/),"/$3( KX9\( #*%*,"-N(,"( "&*( +*;*+($J( "&*(*O$3(5H($J( "&*(C:G](1*3*8( @"( /-( ,3( /340)/I+*(
2$0-*(2$4*+8( @2%$#",3"+'`( "&/-(C:5(2$4*+( #*),%/"0+,"*-( -*;*#*(20-)+*(.,-"/31`(.&/)&(&,-(
3$"(I**3(#*%$#"*4(/3(2$4*+-(/3(.&/)&(4*%+*"/$3($J(:ZBA5(/-("&*(2,/3(J*,"0#*8((
(
(
(
(
(
 
 
 
 
Figure. 5 (PNAS  February 19, 2008   vol. 105  no. 7  2646-2651). EpA960/HSA-Cre-ERT2 mice exhibit severe and 
progressive skeletal muscle wasting and dysfunction after tamoxifen administration. (A) HSA-Cre-ERT2 (Upper) and 
EpA960/HSA-Cre-ERT2 (Lower) littermates 4 weeks after tamoxifen administration. (B) From left to right, the hind 
limbs of age- and sex-matched HSA-Cre-ERT2, EpA0/HSA-Cre-ERT2, and EpA960/HSA-Cre-ERT2 mice 4 weeks 
after tamoxifen administration. Arrows indicate quadriceps and gastrocnemius muscle bodies. (C) Wasting of the 
paraspinous muscle determined by MRI from one HSA-Cre-ERT2 (dashed line) and three EpA960/HSA-Cre-ERT2 
(solid lines) mice during a 4-week time course after tamoxifen administration. Measurements were normalized to the 
kidney diameter.  
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@3( "&*-*( "#,3-1*3/)( 2/)*( *O%#*--/$3( $J( C:G]( *O$3( 5H( )$3",/3/31( */"&*#( X9\( V=M( #*%*,"-(
K>%!X9\N( $#( 3$( #*%*,"-( K>%!\N( .,-( /340)*4( I'( V#*L2*4/,"*4( #*)$2I/3,"/$3( /3(
),#4/$2'$)'"*-a( "&*(,0"&$#-()#$--*4("&*(>%!(+/3*-(./"&(DF!LV#*L>?=7(2/)*`(*O%#*--/31("&*(
",2$O/J*3L4*%*34*3"(V#*L>?=7(#*)$2I/3,-*(-*+*)"/;*+'( /3(-^*+*",+(20-)+*( "/--0*8(=$( /340)*(
#*)$2I/3,"/$3(,34(*O%#*--/$3($J(2?B!(),3",/3/31( "&*(*O%,34*4(V=M(#*%*,"-( k>%!X9\K?Nl`(
>%!X9\PDF!LV#*L>?=7(<( "$(6(2$3"&-( $+4(I/"#,3-1*3/)(2/)*(.*#*( /3g*)"*4(4,/+'( J$#( H(4,'-(
./"&( 5( 21( $J( ",2$O/J*38( >%!\PDF!LV#*m>=?7( I/"#,3-1*3/)( 2/)*( .*#*( ,+-$( "#*,"*4( ./"&(
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skeletal muscle has a number of proteolytic systems including the Ubiquitin-Proteasome System 
(UPS), the Lysosomal degradation, the Ca
++
 dependent degradation, and the Metalloproteinase 
degradation. While Lysosomal degradation and Ca
++
 dependent degradation do not play an 
important role in Muscular Atrophy, since they are not systematically activated during Atrophy, and 
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are not responsible for the major contractile protein degradation, the Caspases and 
Metalloproteinases role in the Atrophyc phenomenon has not yet been elucidated.(
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 6 (Lecker et al. 17 (7): 1807. (2006)) The ubiquitin (Ub)-proteasome System (UPS) of protein degradation. Ub 
is conjugated to proteins that are destined for degradation by an ATP-dependent process that involves three enzymes. A 
chain of five Ub molecules attached to the protein substrate is sufficient for the complex to be recognized by the 26S 
proteasome. In addition to ATP-dependent reactions, Ub is removed and the protein is linearized and injected into the 
central core of the proteasome, where it is digested to peptides. The peptides are degraded to amino acids by peptidases 
in the cytoplasm or used in antigen presentation. Illustration by Josh Gramling—Gramling Medical Illustration. 
 
The most important player in the Atrophic conditions is the Ubiquitin-Proteasome pathway.(The 
Proteasome is found in the nucleus and the cytosol of all cells and constitutes approximately 1 to 
2% of cell mass 
(Voges et al. 2000)
. The 26S particle is composed of approximately 60 subunits and 
therefore is approximately 50 to 100 times larger than the typical proteases that function in the 
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extracellular environment (e.g., in digestion, blood clotting) and differs in critical ways. The most 
fundamental difference is that proteasome is a proteolytic machine in which protein degradation is 
linked to ATP hydrolysis. The 26S complex is composed of a central barrel-shaped 20S proteasome 
with a 19S regulatory particle at either or both of its ends (Figure 6). The 20S proteasome is a 
hollow cylinder that contains the machinery for protein digestion. It is composed of four stacked, 
hollow rings, each containing seven distinct but related subunits. The two outer {alpha} rings are 
identical, as are the two inner beta rings. Three of the subunits in the beta rings contain the 
proteolytic active sites that are positioned on the interior face of the cylinder. The outer {alpha} 
subunits of the 20S particle surround a narrow, central, and gated pore through which substrates 
enter and products exit 
(Grol et al. 2000)
. Substrate entry is a complicated process that is catalyzed by the 
19S particle. This complex architecture evolved to isolate proteolysis within a nano-sized 
compartment and prevents the nonspecific destruction of cell proteins. One can view protein 
ubiquitination and the functioning of the 19S particle as a mechanisms that ensure proteolysis as an 
exquisitely selective process; only certain molecules are degraded within the 20S proteasome. In 
atrophic muscles expression of some specific subunits which are part of the 20S and 19S 
Proteasomal complexes are subjected to variation, strongly suggesting these protein species might 
be limiting entities in the Proteasomal assembly
(Lecker et al. 2006)
. One possibility is that different 
transcription factors, or coregulators could govern particular Proteasomal subunit subgroups 
expression at the level of the muscles 
(Attaix et al. 2003)
. The Ubiquitin-Proteasome degradative pathway 
involves two consecutive steps: the target protein is first poly-Ubiquitinated, thanks to the E1,2&3 
Ubiquitin ligases, (E3 Ligases determine protein specificity) and then recognized by specific 
receptor-proteins (like hRD23B, a cytosolic soluble protein containing an N-terminal ubiquitin-like 
domain, which has been reported to interact with 26S proteasome) involved in the Ubiquitin 
mediated proteolytic pathway targeting the degradation candidate to the 26S Proteasome regulative 
subunits for physical entrance in the 20S catalytic portion and degradation. In a number of 
experiments performed in transgenic mice it turned out that poly-ubiquitinated proteins 
preferentially accumulate at the level of the contractile proteic system of the muscular fibers rather 
than in the soluble protein fraction. Moreover, only ATP depletion or 26S Proteasomal inhibition, 
(for example by MG-132 inhibitor) 
(Lecker et al 2006)
 can efficiently block the release from atrophic 
muscles of 3-Methyl-Histidine. This post-translationally modified amino acid represents a marker 
of the Skeletal Actin and Myosin degradation, reflecting the catabolic rate of the myofibril
(Attaix et al. 
2005)
. Studies in rodent models have also established that accelerated muscle protein catabolism that 
is induced by uremia involves similar cellular mechanisms causing muscle wasting in a variety of 
other catabolic conditions, such as cancer cachexia, starvation, insulin deficiency, or sepsis
(Mitch et al. 
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1996)
. Atrophying muscles from such animals show accelerated proteolysis via the UPS, higher 
levels of mRNAs for certain components of this proteolytic system, and a similar pattern of changes 
(both increases or decreases) in the expression of approximately 100 atrophy-related genes, also 
termed atrogenes 
(Lecker et al. 2004)
. 
Increased ATP-dependent proteolysis by the ubiquitinproteasome System 
Greater sensitivity to proteasome inhibitors Associated with activation of caspase-3 which provides substrates for the 
ubiquitin-proteasome pathway 
Increased conjugation of ubiquitin to muscle proteins 
 
Activation of a common transcriptional program: induction/suppression of a set of atrogenes 
Upregulation of the muscle-specific Ub-protein ligases, atrogin-1/MAFbx and MuRF1 
Suppression of the IGF-1/PI-3 kinase/Akt signaling pathway and activation of FoxO transcription factors 
MuRF-1, muscle ring finger-1; PI3-K, phosphatidylinositol 3-kinase; Ub, ubiquitin; UPS, ubiquitin-proteasome System. 
 
Table 1. Biochemical adaptations found in atrophying skeletal muscles 
 
In humans in similar conditions, there is also evidence for activation of the UPS in muscle (e.g., an 
increase of mRNAs that encode Ubiquitination machinery and proteasome subunits)
(Pickering et al. 2002)
. 
In these catabolic states, the increase in mRNA levels for these Atrophy-related genes in muscle 
occurs through increased gene transcription
(Lecker et al. 2004)
. As part of this common transcriptional 
program, the expression of various growth-related genes decreases in the Atrophic tissues. 
Therefore, multiple transcriptional factors seem to change coordinately to induce the loss of muscle 
mass. The strongest evidence for activation of the UPS in muscles that undergo Atrophy as a result 
of uremia (or other catabolic diseases) is that when studied in vitro, muscles from these mouse 
models, exhibit increased proteolysis that can be blocked by inhibitors of the proteasome 
(Tawa et 
al.1997)
. For these reasons, muscle wasting represents a specific, carefully orchestrated response that 
is triggered by various stimuli in various pathologic conditions (e.g., acidosis in renal failure, low 
insulin levels in fasting and diabetes, inactivity, glucocorticoids or cytokines in sepsis). In fasting 
and presumably in other disease states, an identifiable function of accelerated proteolysis is to 
mobilize amino acids from dispensable muscle proteins to provide the organism with precursors for 
hepatic gluconeogenesis or for new protein synthesis
(Mitch et al 1996)
. However, these losses can have 
deleterious effects with time, especially in renal failure, in which disposal of nitrogenous waste is 
compromised. Because the UPS serves for many essential functions in cell regulation and 
homeostasis, its activation in these states must be highly selective and precisely regulated to avoid 
the unwanted removal of muscle proteins that are essential for cell function in muscle and other 
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organs. Whereas atrophy seems to affect all muscle cell components, contractile proteins are lost 
differentially. The specificity of the UPS in protein breakdown is determined by the cell’s content 
of Ubiquitin ligases (E3s), which, as discussed, target specific sets of proteins to degradation. The 
cellular content of E3s varies among tissues and physiologic states. Two Ubiquitin ligases, atrogin-
1 (also known as MAFbx) and MuRF-1, are specific constituents of muscle: their expression 
increases dramatically (eight- to 20-fold) in catabolic states, and they play a critical role in 
mediating the loss of muscle proteins. 
 
 
 
 
 
 
 
 
Figure. 7 Lecker et al. 17 (7): 1807. (2006)) The balance between protein synthesis and degradation determines whether 
muscles undergoes hypertrophy or atrophy. With hypertrophy, protein synthesis exceeds degradation because the 
phosphatidylinositol 3 kinase (PI3-K)/Akt pathway stimulates protein synthesis and phosphorylates the FoxO 
transcription factors that stimulate protein degradative processes. In diseases that suppress insulin/IGF-1 signaling, the 
PI3-K/Akt pathway is depressed, leading to decreased protein synthesis and FoxO phosphorylation. This allows FoxO 
to stimulate the expression of the E3 enzymes atrogin-1 and muscle ring finger- 1 (MuRF-1) and protein degradation 
In mice that lack genes for atrogin-1 or MuRF-1, muscles grow normally, but if they are 
denervated, the rate of muscle atrophy is reduced
(Bodine et al. 2001)
. Muscles of these knock-out mice 
also show reduced atrophy upon fasting. In wild-type animals that are subjected to muscle 
denervation or disuse, expression of atrogin-1 and MuRF-1 rises quickly just when muscle atrophy 
occurs, and in cultured muscle cells, the content of atrogin-1 mRNA tightly correlates with the rate 
of protein breakdown
(Sandri et al 2004)
. Therefore, the muscle’s content of atrogin-1 mRNA is an 
excellent biomarker for the rate of proteolysis and rapid wasting.  
The COP9 signalosome (CSN) complex is highly conserved from yeast to human. Although the 
plant CSN was first identified as a negative regulator of photomorphogenesis, the mammalian CSN 
is linked to different biological responses such as checkpoint control, signal transduction, 
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development and the cell cycle 
(Kato et al. 2009)
. Frequent over-expression of the CSN subunit in a 
variety of human cancers suggests its involvement in cell transformation and tumorigenesis. The 
best-known biochemical function associated with the CSN is the control of protein stability via the 
ubiquitin-proteasome system through regulation of cullin-RING-E3 ubiquitin ligase activity by 
deneddylation, by controlling the activity of COP1 E3 ligase, or by counteracting ubiquitin-
mediated degradation through a CSN-associated deubiquitinating enzyme. In addition to affecting 
the stability of transcription factors, CSN may regulate gene transcription by directly associating 
with chromatin. Recent studies were directed to understand which transduction pathway influences, 
at the skeletal muscles level, the Ubiquitin-Proteasome System: it seems that Insulin, and Insulin 
like Growth Factors
(Glass et al. 2005)
 negatively regulate this type of degradation, while Cytokines and 
Myostatin activate the system. As noted, once again activation of the UPS in various types of 
muscle wasting and the coordinated changes in the expression of a set of genes in muscle, suggest 
that these catabolic states activate a common cellular signaling pathway
(Lecker et al. 2004)
. Recent 
studies have established that in fasting and, presumably, in other insulin-deficient conditions, the 
fall in protein synthesis and the rise in proteolysis are coupled events that occur through decreased 
signaling of the phosphatidylinositol 3-kinase/Akt (PI3-K/Akt) pathway, which in normal 
individuals is activated by Insulin or IGF-1
(Lee et al. 2004)
. IGF-1 is released by the liver and mediates 
the anabolic effects of the growth hormone, but it is also an autocrine factor released by muscle 
after exercise. In fasting and disease, when insulin signaling is low, the activity of PI3-K is reduced 
and there is less production of phosphatidylinositol-3,4,5 phosphate, the active product of PI3-K; 
the decrease in this regulatory molecule decreases the phosphorylation and activity of the 
serine/threonine protein kinase Akt (Figure 7). Activated Akt is a major activator of growth-related 
processes, and, when overproduced, Akt causes muscle hypertrophy via phosphorylation of the 
downstream kinases glycogen synthase kinase 3 beta (GSK3beta) and mammalian target of 
rapamycin (mTOR)/S6kinase, which enhances global protein synthesis. In many types of atrophy, 
the reduction of PI3-K/Akt pathway leads to reduced mRNA translation and protein expression. 
However, rapid atrophy also requires enhanced proteolysis and induction of E3 atrogin-1 and 
MuRF-1, leading somehow to enhanced protein degradation in muscle cells
(Stitt et al. 2004)
. These 
results show that activation of protein degradation and induction of these E3 enzymes in atrophying 
muscles also result from a decrease in the activated Akt (i.e., phosphorylated Akt). One of the 
targets of activated Akt is the forkhead family of transcription factors (FoxO1, 3, and 4). When they 
are not phosphorylated, they migrate into the nucleus and catalyze the transcription of atrogin-1 
(Sandri et al. 2004).
 Conversely, insulin and IGF-1, by activating PI3-K and Akt, phosphorylate FoxO and 
suppress atrogin-1 expression.  
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As we described above, Insuline resistance is one of the main sympomatical feature of the DM 
pathology. The IR-A splicing isoform of Insulin Receptor, which is referred to as the foetal isoform, 
is characterized by the exclusion of the exon 11, and this negatively affect the receptor affinity for 
Insulin and Insulin-like Growth Factors. It could be therefore important, to investigate whether this 
is one of the triggering causes of Atrophy in DM patient’s skeletal muscles. Besides controlling the 
expression of E3 Ubiquitin ligases, activation of the insulin/IGF-1–-PI3-K/Akt pathway suppresses 
activation of caspase-3. This would decrease the breakdown of the complex structure of muscle 
proteins. In insulin-deficient rats that exhibit accelerated muscle protein degradation, it has been 
evaluated that the proapoptotic factor Bax is activated, leading to the release of cytochrome c from 
mitochondria, which in turn activates caspase-3 and increases production of the 14-kD actin 
fragment
(Lee et al. 2004)
. Similar changes were observed in cultured muscle cells by genetic or 
pharmacologic inhibition of PI3-K activity. Together, these data provide evidence that activation of 
muscle protein loss occurs through a common signaling pathway that alters transcription of key 
enzymes modulating protein synthesis and degradation in a complementary way to cause muscle 
wasting. A recent work by Huichalaf et al., (2009) revealed that DM2 muscle cells are characterized 
by reducted rate of global translation. These data provide additional evicence that CCUG repeats 
might cause pathological alteration of the steady state between protein synthesis and degradation 
leading to the Atrophic phenomenon. The authors present evidence for Znf9 protein to bind to the 
5’ UTR of a number of TOP mRNAs, including Ribosomal Protein RPS17, PABP1 and two 
elongation factors eEF1A and eEF2. Under normal conditions Znf9 supports translation of TOP-
containing mRNAs since direct inhibition of Znf9 by siRNA in normal cells leads to the reduction 
of these proteic species. The reduction of these proteins correlates with the reduction of the protein 
synthesis rate. Dr. Timchenko’s group demonstrated that the reduction of the cytosolic levels of 
Znf9 protein in myoblasts can be triggered by the CCTG expansion, since ectopic expression of the 
pure mutant CCUG repeats reduces the level of Znf9 and of proteins such as RPS17, PABP1, and 
two elongation factors, eEF1A and eEF2. Although the main result of this work was the evaluation 
of a reduction of the total rate of protein synthesis in DM2 myoblasts, which occurs after Znf9 
depletion, the authors cannot exclude multiple causes for this feature, as they previously showed 
CUGBP1 as a translational regulator in DM1 myoblasts
(Salisbury et al. 2008)
. Depending on the CUGBP1 
phosphorylation state, it may have positive or negative effects on the translation machinery. In 
DM2 cells CUGBP1 might reduce translation, or increase degradation of mRNAs encoding 
translational apparatus factors. CCUG repeats interact with CUGBP1-eIF2 complex and with the 
proteasome, hence, the reduction of the translational rates in DM2 cells, could also depend on the 
sequestration of the initiation factor eIF2, or as a result of proteasome dysfunction.  
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However, whether the cause of the progressive
 
muscle wasting, in particular atrophy of fast type 
muscle fibers, rather then general muscle atrophy, could depend on impaired steady state between 
protein synthesis and degradation, or on mitochondrial dysfunction, or on impaired differentiation 
of satellite muscular stem cells into muscle fibers, has yet to be completely explained. Therefore the 
effects of CCTG repeat expansion are likely to extend beyond spliceopathy to include a more 
general disturbance leading to important changes for the physiological role of this muscle tissue.  
Many studies on DM physiopathology are focusing on the alterations occurring at the 
transcriptional and post-transcriptional level, however, the functionality of the biological system 
depends on the availability and activity of  the proteins.  Accessibility of wide-screening techniques 
for the analysis of  global protein expression profile is therefore a suitable approach for the 
identification of  altered protein pattern in the pathologic state as compared to the normal one. To 
investigate this issue, we have used cultured satellite cells obtained from biopsies of DM2 and 
unrelated patients. Under the experimental conditions we have previously set up, these cells can 
differentiate into myotubes with morphologic features and expression of specific differentiation 
markers similarly to control cultures. Moreover, DM2 myoblasts show ribonuclear inclusions, 
MBNL1 nuclear sequestration and splicing abnormalities characteristic of DM2 muscle.   
Our large scale proteome analysis reveals that proteins belonging to two major functional classes 
are altered in DM2 myotubes: components  of the  mitochondrial compartment with particular 
emphasis to mitochondrial proteins involved in import mechanisms such as Hsp60 and GRP75 [also 
referred to as Stress-70
 
protein, mitochondrial precursor (mtHSP70) or Mortalin)] and the 
translational machinery of mitochondria such as EFTu, and proteins belonging to the ubiquitin-
mediated proteasomal system (UPS) suggesting that DM2 pathology affects biological processes 
relevant for muscular function. Moreover, in order to obtain an alternative Human cellular model 
for the study of the DM pathology we produced a skin fibroblasts bank with cells derived from 
DM1, DM2 and control patients, and validated DM2 fibroblasts as a potential candidate for DM2 
mitochondrial impairment, evaluating a differential mitochondrial membrane potential for DM1 and 
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DM2 fibroblasts compared to control cultures, and a faster and more aboundant cytochrome c 
release from the mitochondrial membranes of DM2 fibroblasts after Hydrogen peroxide treatment. 
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3. MATERIAL AND METHODS 
3.1 Patients and primary muscle cell cultures 
Human muscle biopsies from biceps brachii muscle were taken under sterile conditions from DM2 
patients (n = 4) and from unaffected individuals (n = 4). The biopsies were used for this study after 
informed consent from patients. The diagnosis of DM2 was based upon the clinical diagnostic 
criteria set by the International Consortium for Myotonic Dystrophies 
(Moxley et al., 2002).
 The 
histological diagnosis was performed on serial sections processed for routine histological or 
histochemical stainings. Fluorescence in situ hybridization was performed on frozen sections using a 
(CAGG)5 probe as previously reported 
(Cardani et al., 2004)
.  The biopsies from donors were dissected and 
cells were propagated at 37°C as described 
(Cardani et al., 2009)
 Both DM2 and control myoblasts were 
plated at a density of 60,000 per 35 mm dishes and grown in proliferative medium at 37°C. 
Myoblasts were allowed to grow until 80% confluent. To initiate differentiation, the proliferative 
medium was replaced with differentiation medium consisting of DMEM supplemented with 7% 
FBS.   
3.2 Subcellular fractionation  
The cell cultures of each patient were lysed in proper conditions to obtain two fractions: one fraction 
enriched in cytosolic/membrane proteins, and one in nuclear proteins. The cells,  scraped and 
pelleted, were treated with an hypotonic buffer (10mM Hepes pH 7.5, 0,5% NP-40, 10mM KCl, 1 
mM EDTA, 1 mM DTT, additioned with proteases and phosphatases inhibitors). After 15 minutes of 
mild agitation, cells were centrifuged at   400xg  at 4°C.The supernatant was then centrifuged at 
15000xg  to clarify the extract and the supernatant representing the cytosolic/membrane enriched 
fraction, was collected. The  pellet obtained from the 400xG centrifugation was treated with an 
hypertonic buffer, (20mM  TRIS-HCl pH 7.5, 0,6 M NaCl, 0,2 mM EDTA, 1,4 mM MgCl2 25%  
glicerol, and proteases and phosphatases inhibitors) with mild agitation for 15 min at 4°C and then 
centrifuged at 80.000xg at 4°C. The supernatant was collected and represent the nuclear-enriched 
fraction. 
In order to obtain the cytosolic fraction of soluble proteins from fibroblast cultures the cells were 
washed 3 times with PBS then homogenized in 1 ml of ice-coldbuffer A [20 mM HEPES, pH 7.5, 
320 mM sucrose, 1 mM ethylenediaminetetraacetic acid (EDTA), 5 mM ethylene glycol tetraacetic 
acid (EGTA), 5 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
sodium orthovanadate, 10 mM NaF, 10 mM sodium pyrophosphate, 10 mM !-glycerophosphate, 
supplemented with complete EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, 
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Germany)]. 8 up and down syringe cycles were performed at 4° on the cell extract in order to destroy 
the cells properly, the collected homogenate was then centrifuged at 100,000°—g at 4°C for 1 h. 
Soluble cytosolic proteins were found at the level of the supernatant. 
3.3 Two-dimensional Gel Electrophoresis (2D-GE)   
Protein were processed essentially as described 
(Colombo et al., 2009)
, Each sample containing 100 µg 
proteinsfor the citosol and 50 mg for the nuclei  was precipitated using a chloroform/methanol 
protocol and resuspended in a solution containing 7 M urea, 2 M thiourea, and 4% CHAPS. The 
first dimension was carried out with an 18-cm pH 3–10 non-linear gradient IPG strip (GE 
Healthcare). Strips were  focused at 20°C for a total of 70,000 Vh at a maximum of 8,000 V using 
the Ettan IPGphor II system. For the second dimension, IPG strips were equilibrated in a solution 
containing 6 M urea, 2% SDS, 30% glycerol, and 50 mM Tris/HCl pH 8.8. DTT (10 mg/ml) and 
iodoacetamide (25 mg/ml) were respectively added to the first and to the second steps. IPG strips 
were placed on top of a polyacrylamide gel (12% T, 3,3% C) and run using the Ettan DALTsix 
system (GE Healthcare). Gels were then fixed and stained with 1:200 dilution of Epicocconone 
fluorescent stain (Deep Purple, GE Healthcare). Gel images were acquired with a Typhoon scanner, 
using green laser (532 nm) for the excitation of the fluorophore and 610BP filter to capture emitted 
light. The digitalized gel images were analyzed with Image Master 2D Platinum software (GE 
Healthcare). Normalized spot volumes of individual proteins expressed as mean ± standard 
deviation were used to perform Student’s t test setting the significance level at p<0.05. Only spots 
present in all four samples of DM2 and control cultures (both for the cytosolic and nuclear fraction) 
that show statistically significant differential expression were considered. 
3.4 Protein Identification by Matrix-assisted Laser Desorption/Ionization-Time of Flight (MALDI-
TOF) MS Analysis    
Proteins were identified after excising bands from  the stained gels and processed as described 
(Gorla 
et al., 2006)
. MALDI-TOF mass spectrometry was carried out using a Voyager-DE STR (Applied 
Biosystems, Framingham, MA) equipped with a nitrogen laser (337 nm). Mass spectra of tryptic 
peptides were acquired operating in the positive ion, delayed extraction and reflectron modes using 
-cyano-4-hydroxycinnamic acid (5 mg/mL in 50% acetonitrile with 0.1% trifluoroacetic acid) as 
the UV-absorbing matrix. Analytes were prepared by spotting 2 "L of supernatant on the target 
(384-sample plate with hydrophobic surface, Applied Biosystems), drying with a gentle air flow, 
and addition of 0.35 "L of matrix solution. Experimental conditions were as follows: accelerating 
voltage 20 000 V; grid voltage, 68%; guide-wire voltage, 0.000%; delay time, 250 ns; laser power, 
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2400 a.u. After acquisition, the spectra (resolution 15 000) were processed by Data Explorer 
software (version 4.0, Applied Biosystems) applying default parameters for advance baseline 
correction (peak width, 32; flexibility, 0.5; degree, 0.1), deisotoping algorithm, internal mass 
calibration (using autolysis trypsin peptides 842.5100 and 2211.1046 m/z) and peak detection. 
Monoisotopic peptide masses were analyzed rising ProFound software 
(http://129.85.19.192/profound_bin/webprofound.exe 4.10.5) or Aldente software 
(http://www.expasy.ch/tools/aldente/). Input was searched according to the following databases: (1) 
ProFound: NCBI (nonredundant protein sequence database); taxonomy category: mammalian; 
digest chemistry: trypsin; max missed cut: 1; modification: cysteine alkylation with iodoacetamide 
(complete), oxidation at methionine (partial); charge state MH+; monoisotopic tolerance: 20 ppm. 
Protein peaks recognized by the software were removed automatically based on a Z score greater 
than 1.65 (95% percentile); and (2) Aldente: UniProtKB/SwissProt; predefined taxon: Mammalia; 
Spectrometer internal error max: 25.  
3.5 Immunoblot Analysis    
For monodimensional immunoblot analysis, samples were then resolved in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose Protran 
Membranes (Schleicher Shuell). The membrane were probed with different primary and the proper 
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories,). 
Chemioluminescent signals were detected using the ECL detection system (GE Healthcare). Band 
intensities were quantified by densitometry with Scion Image Program (Scion Corporation) using 
GAPDH signals as internal control.  
3.6 FISH 
For fluorescence in situ hybridization (FISH) fibroblasts were fixed with 2% formaldehyde in PBS 
for 30’ at 4°C. A Texas Red labelled (GAGG)5 probe (IDT, Coralville, IA, USA) was used as 
previously reported by Cardani et al (2004, 2009). Fixed fibroblasts were permeabilized with 2% 
acetone in PBS (pre-chilled at -20°C) for 5’. After washing in PBS, cells were incubated in 30% 
formamide, and 2% SSC for 10’ at RT, and then hybridized with the probe (1ng/ml) for 2 hours at 
37°C in 30% formamide, 2% SSC, 0,02% BSA, 67 ng/ul yeast tRNA, 2 mM vanadyl 
ribonucleoside complex. Cells were washed in 30% formamide, 2X SSC at 45°C for 30’ then 
washed 5 times in OBS for 3’ at RT, and pre-incubated with normal goat serum (DAKO, Denmark) 
at the diluition 1:20 in PBS containing 2% BSA. 
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3.7 Reagents and antibodies 
The reagents for 2D-GE were from GE Healthcare. Mouse monoclonal anti-PDI  were purchased 
from Santa Cruz Biotechnology, anti ubiquinated proteins (clone FK2) were from Affiniti, anti 
PARP were from BD Pharmingen . Anti actin (rabbit polyclonal) anti Tubulin (mouse monoclonal) 
anti GAPDH (rabbit polyclonal) were purchased from Sigma. Polyclonal antibodies directed against 
EFTu/Ts were a generous gift from L. Spremulli (Chapel Hill, NC, USA) and antibodies against 
CLIC1 were a kind gift from M Berryman (Ohio University College of Osteopathic Medicine 
Athens, Ohio USA) 
3.8 JC1  
Fibroblasts were grown in 96 well plates at the average concentration of 10000 cells/plates in 
DMEM 10% FBS, washed 3 times with PBS before adding the JC1 working solution. 100 ul/well 
of this solution were added. The cells were incubated with the dye at 37°C for 1 hour, then the 
compound was removed and the cells washed 3 times with PBS. With the fluorimeter the 
fluorescence intensity was evaluated. Excitation wave length: 490 nm, fluorescence emitted at 590 
nm (orange), and 525 nm (green) were evaluated as a ratio Orange/Green. 
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4. RESULTS  
4.1 Proteomic analysis 
In this study we have used myotubes derived from satellite cells of DM2 patients and of unrelated 
control biopsies, as an  experimental in vitro model  to search for  global alteration of human DM 2 
muscle cells protein expression profile. For our large scale proteome analysis we used cells that 
have been differentiated in vitro along the myogenic lineage for 10 days. 
To investigate alterations of single proteins in DM2 myotubes as compared to the control ones, we 
used two-dimensional gel electrophoresis (2D-GE) and mass spectrometry analysis (MS). 
Moreover, we fractionated cellular extracts to cytosol/membrane enriched, and also nuclear 
fractions to allow the enrichment of low abundance proteins. 
 
 
Figure. 8 Subcellular fractionation allows to enrich for specific compartment-localized proteins. Myotubes were 
fractionated according to the protocol described under Material and methods and analysed by immunoblotting using 
specific antibodies. 
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Both fractions were initially checked for the expression of specific markers. As shown in  Fig. 8, 
Poly-(ADP-ribose) polymerase (PARP)  and muscleblind, two nuclear proteins, are highly enriched 
in the nuclear fraction, while tubulin is mainly present in the cytosol confirming data from the 
literature and indicating that our procedure allowed the enrichment of specific compartment-
localized proteins. As expected, Actin was present in both nuclei and cytosol.  Cultures obtained 
from 4 DM2 and 4 control biopsies were fractionated and the different fractions (i.e.cytosolic and  
nuclear) of the 8 samples were independently separated by 2D-GE, stained with Deep Purple and 
the 2D-gel maps were acquired as digitalized gel images. We decided to use this fluorescent 
compound to visualize the proteic spot as it is characterized by a wide dynamic range, allowing a 
quantitatively reliable comparative expression analysis. Only spots present in all the gels (for each 
fraction) were analyzed and the normalized spot percentage of volume of individual proteins was 
statistically evaluated (see methods) QRepresentative two dimensional images are shown in fig 9 
and fig 10, respectively referred to the cytosolic  and to the nuclear fractionated proteins. 
 
Figure. 9 Two-dimensional map of cytosolic enriched proteins. A representative two-dimensional gel electrophoresis 
image obtained using cytosolic-enriched fraction from myotubes. Cytosolic proteins obtained from 10 days 
differentiated myotubes were focused on pH gradient (3–10 NL) separated on 12% polyacrylamide gel and stained with 
deep purple. Image analysis performed as described under Material and methods, evidences 17 significantly altered 
spots (p<0.05) in DM2 cultures as compared to control one. The differentially expressed spots were numbered and 
identified by mass spectrometry (with the exclusion of spots C9, C10 and C11) and correspond to the data presented in 
Table 2. 
About 2000 proteic spots were detected in the cytosol while 1200 spots were identified in the 
nuclei. Those spots that were statistically significantly altered  (p<0,05) (17 spots for the cytosolic 
fraction and 7 from the nuclear one)  were cut, analyzed by MALDI-TOF, identified by data base  
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Figure. 10 Two-dimensional map of nuclear enriched proteins from myotubes . A representative two-dimensional gel 
electrophoresis image obtained using nuclear-enriched fraction from myotubes. Nuclear enriched proteins were 
analysed as above and image analysis evidences  significantly altered spots (p<0.05). The differentially expressed spots, 
were numbered and identified by mass spectrometry (with the exclusion of spots N1, N3, N4, N7) and correspond to the 
data presented in Table 2. 
search and classified into functional categories according to Gene Ontology. The data are reported 
in Table 2 and Figure 11. 
 
Table. 2 Spots differentially expressed in DM2 myotubes.  Relative spot on 2D MAP (Fig. 2 and Fig. 3);   AC indicates 
SwissProt Accession Number; Cov, sequence coverage (%); DE, description; ID, identified protein; Mw, molecular 
weight; pI , isoelectric point,  p value confidence value obtained from t test with 6 degrees of freedom, volume: volume 
of the spot in the two conditions considered; percent variation: increase or decrease in DM2 cultures relative to control 
one. 
 
 
ID SPOT SCORE AC DE MW PI COV CTRL DM2 
P-VALUE 
B 
PERCENT 
VARIATION 
GRP75_HUMAN C1 47.13 P38646 Stress-70 protein, mitochondrial. 69 5.5 44 0.6 0.022 0.01 !! 96% 
CH60_HUMAN C2 34.33 P10809 60 kDa heat shock protein, mitochondrial... 58 5.2 32 1.2 0.79 0.05 !! 34% 
RD23B_HUMAN§ C3 33.39 P54727 UV excision repair protein RAD23 homolog... 43 4.8 25 0.073 0.021 0.01 !! 71% 
K1C16_HUMAN C4 30.44 P08779 Keratin, type I cytoskeletal 16. 51 5 36 0.02 0.05 0.05 + 150% 
PDIA3_HUMAN C5 98.72 P30101 Protein disulfide isomerase A3. 54 5.6 40 0.11 0.072 0.01 !! 34% 
PDIA3_HUMAN C6 60.92 P30101 Protein disulfide isomerase A3. 54 5.6 33 0.25 0.16 0.01 !! 36% 
AL9A1_HUMAN C7 80.04 P49189 4-trimethylaminobutyraldehyde dehydrogen... 54 5.7 35 0.05 0.086 0.001 + 72% 
VAT1_HUMAN C8 31.59 Q99536 Synaptic vesicle membrane protein VAT-1 ... 42 5.9 28 0.068 0.024 0.01 !! 64% 
CLIC1_HUMAN C12 97.05 O00299 Chloride intracellular channel protein 1... 27 5.1 60 0.036 0.016 0.05 !! 55% 
ECH1_HUMAN C13 52.4 Q13011 Delta(3.5)-Delta(2.4)-die noyl-CoA isomer... 32 6 44 0.58 0.22 0.01 !! 62% 
EFTU_HUMAN C14 79.09 P49411 Elongation factor Tu, mitochondrial. 45 6.3 34 0.045 0.024 0.01 !! 46% 
EFTU_HUMAN C15 245.39 P49411 Elongation factor Tu, mitochondrial. 45 6.3 60 0.045 0.023 0.05 !! 48% 
K1C16_HUMAN C16 110.32 P08779 Keratin, type I cytoskeletal 16. 51 5 68 0.02 0.041 0.05 + 105% 
PSD13_HUMAN C17 177.54 Q9UNM6 26S proteasome non-ATPase regulatory sub... 43 5.5 42 0.01 0.039 0.05 + 290% 
CSN4_HUMAN C18 36.39 Q9BT78 COP9 signalosome complex subunit 4. 46 5.5 29 0.038 0.067 0.05 + 76% 
TCPA_HUMAN N2 66.11 P17987 T-complex protein 1 subunit alpha. 60 5.8 27 0.12 0.18 0.05 + 50% 
ERP29_HUMAN N5 47.35 P30040 Endoplasmic reticulum protein ERp29. 26 6.1 40 0.04 0.08 0.05 + 100% 
PSA6_HUMAN N6 52.36 P60900 Proteasome subunit alpha type-6. 27 6.3 49 0.12 0.06 0.05 !! 50% 
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4.2 Results clusterization 
 
 
Figure. 11 Distribution of the identified proteins. Graphic representation of the proteins listed in Table 2 grouped by 
their GO function. 
As one can observe in Figure. 11 we could cluster the variations we found, in a narrow number of 
functional categories: the most important were the mitochondrial related proteins, and the proteins 
related to the UPS. In the first category we isolated EFTu (mitochondrial elongation factor), 
Mortalin (GRP75, or mtHSP70), mtHSP60, and two enzymes related to the fatty acids beta-
oxidation, and to the biosynthesis of Carnitine, the fatty acid transporter along the mitochondrial 
membranes. Among the UPS proteins we found 2 unrelated subunits of the Proteasome: PSD13 
(26S Proteasome non ATP regulatory subunit 13) a component of the 20S core Proteasomal 
complex with proteolysis activity and PSA6, (Proteasome subunit alpha, type 6) a subunit of the 
19S proteasomal regulatory particle. Moreover we identified as changing its level hRD23B (a 
receptor protein that recognizes ubiquitinated proteins and targets them to the regulatory 19S 
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proteasomal particle), and a subunit of the COP9 signalosome (that regulates the E3 Ubiquitin 
ligases and hence the preotasome mediated protein degradation). Also proteins taking part to the 
Unfolded Protein Response (UPR), and in particular ERp29 (Endoplasmic Reticulum protein 29) 
and PDI were isolated as proteins changing their expression levels in DM2 myoblasts. These results 
suggest an implication of the UPR in the pathogenesis of the DM2.  
4.3 Western blotting confirmtions 
We choose a representative proteic species for every functional compartment found out to be 
involved in the expressive variations, confirming CLIC-1 which is a shuttling anion channel which 
is normally soluble but inserts into membranes during oxidative stress events and was ascribed on 
the category “others”and PDI, part of the Reticulum Stress Response together with ERp29.  
 
 
 
 
 
 
 
 
Figure. 12 Confirmation of the proteomic data by immunoblot analysis. Panel A and C  show immunoreactive bands of 
CLIC1 and PDI, respectively. Panel B and D show the band intensity of  PDI and CLIC1 normalized with the intensity 
of GAPDH. The quantification was done on 4 samples of DM2 and 4 samples of the control cultures.  Comparative 
analysis revealed significant reduction of PDI (p<0.05) and CLIC1 (p<.0,01) in DM2 cultures consistent with the 
proteomic data shown. Bars represent the s.d. 
EFTu set down for the mitochondrial implications of the DM2 patient’s myoblasts. For elongation 
factor Tu (EFTu) we identified by bidimensional gel analysis two spots that were recognized with 
EFTu/Ts antibodies (not shown) and confirmed a global reduction of both isoforms of EFTu 
(figure. 13 A and B ).   
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Figure. 13 Level of EFTu and EFTs proteins in DM2 cultures. Panel A: immunoblot analysis with antibodies against 
Tu/Ts to detect the level of EFTu and EFTs in cytosolic extracts of DM2 and control cultures. Panels B and C show the 
average intensity level of EFTu and EFTs after normalization for GAPDH intensity, respectively. The quantification 
was done on 3 samples of DM2 and 3 samples of control cultures in two independent experiments. Comparative 
analysis revealed significant reduction of EFTu (pb0.05), while the level of EFTs was highly variable in DM2 cultures. 
The error bar represents s.d. 
EFTu mitochondrial elongation factor is involved in the organelle specific translation of proteins. 
The consistent reduction of two differently phosphorylated isoforms of this protein suggests a 
possible functional involvement of Mitochondria in the pathogenesis of the DM2. Every 
mitochondrial protein evaluated as differentially expressed in DM2 patient’s myoblasts compared to 
controls, tuned out to be downregulated (see the Table 2 and Fig. 11). A possibility is that a similar 
downregulation can involve the mitochondrial EFTu as we found out, and the cytoplasmic 
elongation factors, eEF1A and eEF2, as the group of Dr. Timchenko showed. These factors may be 
implicated in a lowered global translation rate in DM2 myoblasts. Further analyses are required to 
understand whether mitochondrial elongation factor EFTu mRNA includes a TOP containing 
element in its 5’UTR, and could be regulated by Znf9 binding.  
Since the same antibodies used to detect EFTu, recognize also the EFTs proteins, we measured the 
level of EFTs in the different cultures. Interestingly, we found (fig13 A and B) that while the level 
of EFTs in the different control cultures is constant, it is extremely variable in DM2 cultures 
therefore affecting the Tu/Ts ratio.( 4± 0.028 for control and 4 ± 0.862  for DM2 cultures). The 
EFTs factor acts as a nucleotide exchange factor for EFTu, and the stoichiometry between the two 
factors is important in order to determine the translation process efficiency.  
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4.4 Functional aspects 
A consistent group of proteins that were altered in our proteomic analysis, belong to the ubiquitin-
proteasome system. For this category we decided to use a different method in order to confirm the 
accuracy of the proteomic analysis: the indirect evaluation of the functional involvement of the UPS 
through the evaluation of a differential amount of ubiquitinated proteins. To investigate if these 
alterations affect the ubiquitination state of proteins we used antibodies that recognize ubiquitin-
protein conjugates (both mono and poly-ubiquitinated).  
 
 
 
 
 
 
 
 
 
Figure. 14 The level of ubiquitinated cytosolic proteins is reduced in DM2 cultures. Cytosolic extracts of control and 
DM2 cultures were analyzed with antibodies against ubiquitin-protein conjugates. The quantification was done on 3  
samples of DM2 and 3 samples of the control culture. The relative  intensity of the blot was normalized for GAPDH 
and the data are shown in panel B. (p<0.01). The bar represents the s.d. 
As one can observe in Fig. 14, it is obvious that an altered steady state of the ubiquitinated proteins 
occurs in DM2 myoblast compared to controls, further supporting implications of the UPS in the 
DM2 disease. We were also interested in further understanding the mechanisms underlying the 
results observed. A diminished amount of Ubiquitin–Protein conjugates, infact, suggests either an 
impairment of the ubiquitinations enzimatic machinery, or an augmented proteasomal functionality, 
able to more efficiently degrade the Ubiquitinated proteins. Administration of the proteasomal 
inhibitor MG-132 to the culture medium, could give some more indications about the processes 
involved. In treated DM2 myoblasts we found out increase of the conjugates after proteasomal 
inactivation, suggesting not only a higher efficiency, enhanced degradation rates for the proteasome 
 36 
accomplishing its task, compared to control cultures, but also higher Ubiquitination rates, 
correlating with a sealed overexpression of CSN4 subunit of COP9 signalosome. This is a cellular 
multiproteic complex controlling the Ubiquitination process. The COP9 signalosome may play an 
important role in mediating E3 ubiquitin ligase–mediated responses since it is implicated in the 
regulation of cullin-RING type E3 ubiquitin ligases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 15 Effect of proteasome inhibitor on the level of ubiquitinated cytosolic proteins. Control and DM2 myotubes 
were treated (or not) with MG132 (10 µM) for 4 h. Cytosolic extracts were then prepared as described in Materials and 
methods and analyzed with antibodies against ubiquitin–protein conjugates and tubulin. A: a representative gel. B: 
Densitometric analysis: the average intensities of ubiquitinated proteins normalized for tubulin were determined for 
control and DM2 samples and the data were expressed as fold increase over the untreated condition. The quantification 
was done on 4 DM2 cultures and 4 control samples. The error bar represents s.d. 
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Figure. 16 FISH localization of ribonuclear inclusions. Foci can be observed in the DM2 fibroblast nucleus. Probe: 
(CAGG)5 fluorophore, Texas Red. 
We decided to test whether DM fibroblasts, had a functional impairment in the protein degradation 
processes. As we evaluated for DM2 myotubes. 
 
 
 
 
 
 
 
 
 
Figure. 17 Effect of proteasome inhibitor on the level of ubiquitinated protein. A total extract was analyzed. DM2 DM1 
and control fibroblasts were treated (or not) with MG132 (10 µM) for 4 h. A: a representative immunoblot. B: 
Densitometric analysis: the average intensities of ubiquitinated proteins normalized to tubulin were determined for 
DM2 DM1 and control samples and the data were expressed as fold increase over the untreated condition. The 
quantification was done on 4 DM2, 4 DM1 cultures and 4 control samples. The error bar represents s.d. Fibroblast 
obtained from DM2 and DM1 patients do not reveal an increased Ubiquitin-protein conjugates amount over the basal 
condition after MG-132 treatment compared to control fibroblasts.  
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A positive response would have been used to further understand the mechanisms underlying such 
an impairment in the new cellular model, like the behaviour of important muscular E3 Ubiquitin 
ligases like Atrogin-1 or MuRF-1, or the caspases-3 activation.  
Fibroblasts obtained from DM1, DM2 and control patiens were grown to 80% confluence and 
treated with MG-132 proteasomal inhibitor, (10"M for 4hs). Untreated control cells for all of the 
three experimental conditions were used in parallel. We extracted the total protein and performed 
SDS-PAGE. The immunoblot analysis was done using the antibody against the mono- and poly-
Ubiquitinated protein cojugates, the results presented in figure 17 do not indicate an altered level of 
ubiquitinated conjugates over the basal condition after the MG-132  treatments. Differently from 
what observed in myoblasts it is possible that in the fibroblast model the presence of Ribonuclear 
inclusions (RNP) does not affect the degradation machinery. 
Two major cellular systems were indicated by the proteomic analysis as possibly involved in the 
pathogenesis of the Myotonic dystrophy type 2. The Ubiquitin Proteasome System (UPS) and the 
Mitochondrial compartment. We noticed that while human myoblasts show a functional peculiarity, 
compared to controls, for what concerns the degradation processes, human DM fibroblasts do not 
follow a similar pattern either for Ubiquitin-conjugates downregulation or for higher increase of 
Ubiquitin-conjugates after blocking proteasomal activity. This suggests that proteasomal 
abnormalities could be triggered in a cellular specific fashion, depending on the myogenic genes, or 
on the genes specifically expressed in mucle cells. We are confident about the possibility in the 
future to evaluate proteasomal involvement at the level of the fibroblasts once these cells are 
adenovirally converted to the myogenic leneage, being this research our further planned step. 
Mitochondria are involved in DM2 at the level of different gene products. As we already described 
above two isoforms with different isoelectric point of the Translation Elongation Factor Tu, a key 
enzime acting in the metabolic mitochondrial process of the beta-oxidation of fatty acids, and two 
important HSP proteins, Mortalin and mtHSP60 turned out to be downregulated in DM2 myoblasts. 
A fast and interesting test to gain informations on the mitochondrial functionality is the evaluation 
of the mitochondrial resistance to oxidative stress, in terms of release of cytochrome c from the 
mitochondrial inner membranes. Release of cytochrome c from mitochondria is therefore 
considered a key initial step in the apoptotic process, although the precise mechanisms regulating 
this event remain elusive.(Mitochondria anyway have received considerable attention as principal 
source and target of ROS. Cytosolic superoxide may modulate cytosolic factors such as Bax, Bid, 
or caspase-8, all of which have been linked to the release of cytochrome c and the initiation of 
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apoptosis 
(Jurgensmeier et al., 1998; Narita et al., 1998)
. Bax mRNA has been shown to be up-regulated in insulin 
resistant mice, but more likely, the pathologic behaviour of DM2 mitochondria witnesses their 
inability to respond to a oxidative stress source. In order to preliminarly evaluate whether 
fibroblasts obtained from DM2 patients could present macroscopic mitochondrial differences with 
respect to control cells, we decided to test the mitochodrial membrane potential of our cells, using a  
 
 
 
 
 
 
 
 
 
 
 
Figure. 18 Fibroblasts derived from DM2 and DM1 patients reveal a hyperpolaryzation of the membrane potential. The 
photograph shows a representative fluorescence microscope field, of fibroblasts treated with the JC1 compound. The 
histogram shows the ratio orange/green fluorescence arbitrary intensity* for DM2, DM1 and control patients derived 
fibroblasts. 
 
colorimetric compound called JC1. This dye is capable to aggregate in a potential dependent 
manner. Being monomeric in the cytosol, it emits green fluorescence, and aggregates in the 
mitochondria in a potential proportional fashion, emitting on orange fluorescence. The JC-1 
compound enables to normalize the data on the total amount of cytosol volume, because it is 
capable to enter the mitochondria, but it also stains the cytosolic compartment, where the signal 
emitted is green. This is important since the ratio of the orange/green fluorescence emitted, is a 
value independent on the number of cells, and the great number of cells evaluated at the fluorimeter 
renders a statistical randomization of the citosolic emitted fluorescence even if the shapes of the 
cells, or the standard deviation of the cellular size are considerably wide. In our evaluation the 
tested fibroblasts from patient with respect to control show an average 35% hyperpolaryzation in 
the mitochondrial membrane potential, both from DM2 and DM1 patients as compared to controls. 
We also treated DM2, DM1 and control fibroblasts with H2O2 to induce the release of cytochrome c 
from the mitochondria to the cytosol. Cells were fractionated to isolate cytosolic fractions that were 
analyzed by immunoblot analysis using antibodies against cytochrome c. As shown in Fig. 19, 
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H2O2 treatment induces the release of cytochrome c in the cytosol. This release was markedly 
higher for DM2 fibroblasts. However it is interesting to note that in DM2 mitochondria, the basal 
cytosolic cytochrome c is lower than that of DM1 cells. These results might suggest substantial 
differencies between DM1 and DM2 mitochondria that requires further analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 19 – DM2 fibrobasts release more citochrome c compared to DM1 and controls, after treatment with H2O2. 
Moreover the basal release of this small protein seems to be lower. Panel A: immunoblot image of cytosolic extracts of 
DM2, DM1 and control fibroblasts, treated and untreated with hydrogen peroxide, cytochrome c is evidenced thanks to 
the specific antibody. Panel B: densitometric obtained intensity comparison normalized to the ERK intensity. The 
histogram represents the ratio between the cytochrome c signal after the treatment with peroxide, and the basal release 
of this protein. The experiment was performed three times on the same fibroblasts extracts (Peroxide treatment: 4 hs, 
1mM). Bars represent s.d. 
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5. DISCUSSION 
In this study we have undertaken a proteomic approach to identify functional differences at the 
protein level between DM2 cell cultures and control ones. Proteome analysis of skeletal muscle 
cells has been used under physiological and pathological conditions, however such a study has 
never been undertaken to analyze the Myotonic Dystrophy pathology. We have used satellite cells 
from DM2 biopsies according to the criteria set by the International Consortium for Myotonic 
Dystrophies 
(Moxley, et al. , 2002).
 The cells were grown in vitro and induced to differentiate into 
myotubes. This cellular model retains many of the features of adult DM2 muscle cells with the 
advantage to allow a wide screen proteome analysis not possible with the small dimension of the 
biopsies. Our proteome analysis revealed that 25 spots were altered in DM2 cultures as compared to 
control ones. Of these 7 were isolated in the nuclear enriched faction while 18 were mainly 
cytosolic proteins. Interestingly, these changes were statistically significant, even if the biopsies 
from which the cells were derived were neither matched for age, gender or length of the 
microsatellite expansion. It is also possible that using satellite cells (i.e muscle-specific stem  cells) 
induced to differentiate in vitro we worked with a more homogeneous population, thus reducing the 
differences. Interestingly, for some of the spots that we did not analyze (since they were not 
statistically different in the wise pair comparison) we also found spots that were highly similar in 
their volume in the control condition but significantly divergent in DM2 cultures (see the results for 
EFTs). A greater sampling and a improved sorting of DM2 patients may be relevant to this issue. 
Our analysis was done by fractionating the cellular extracts in a cytosolic/membrane (Triton X-100 
soluble)  enriched fraction and a nuclear one to enrich for low abundance proteins. By this approach 
we have however discarded the cellular Triton insoluble fraction that contains mainly sarcomeric 
proteins (Myosin, etc) and of which we did not carry out any functional proteome comparison. The 
proteome analysis points to variation in the spot volume in some cases also greater than two-fold 
with a general tendency to a reduction rather then increase as compared to control cultures. The 
proteins identified by mass spectrometry were 17 out of 25. The overall picture that emerge from 
our analysis is that the proteins changing their level of expression can be clustered in a reduced 
number of functional categories. As shown in figure 11 we found proteins involved in 
mitochondrial biogenesis and function, proteins of the degradation machinery and proteins involved 
in the protein folding. Among the proteins involved in folding machinery of the ER we detected 
reduction of two isoforms of protein disulfide isomerase (PDI-A3), a chaperon protein that mediates 
protein folding by promoting formation of disulfide bonds. In parallel we found an increase of 
ERp29, another chaperone protein of the ER that does not have enzymatic activity and is usually 
induced following ER stress.  Secretory proteins become folded and acquire stabilizing disulfide 
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bonds in the ER. Correct disulfide bond formation is a key step in ER quality control, where 
proteins with incorrect disulfide bonds are recognized by the quality control machinery and are 
retrotranslocated into the cytosol where they are degraded by the proteasome 
(Ellgaard et al., 1999)
. 
Reduced expression of PDI may impair the normal capability of the ER to correctly fold the ER 
proteins, while ERp29 level increase is consistent with the Dr. Timchenko’s group results 
(Salisbury et 
al. 2009)
 concerning the increase of Bip, and its comcomitant sequestration by CCUG the repeats 
amplificated RNA, suggesting issues in the Unfolding Protein Response by the DM2 myoblasts ER. 
Our results also indicate changes in proteins involved in the ubiquitin-proteasomal system. We 
found increase of 26S proteasome non-ATPase regulatory subunit 13, as well as for a subunit of the 
19S proteasomal regulatory particle that binds, unfolds and translocates ubiquitinated proteins into 
the proteasome core 
(Coux et al., 1996)
. Also a subunit of COP9 signalosome complex, part of a 
regulatory particle of the ubiquitin-proteasomal system whose function has not yet completely 
defined 
(WeiandDeng, 2003)
,  is increased in DM2 cultures. It seems that COP9 signalosome could be 
implicated in the regulation of the ubiquitination process via the control of E3 ubiquitin ligases, as 
we discussed in the Introduction. In parallel we found reduction of one of the catalytic subunits of 
the 20S core (alpha-6) indicated as a sequestered protein as well by Salisbury et al. in 2009. A 
possible explaination is that we evaluated this protein as reduced because during the fractionations 
performed prior to our analysys large RNA protein complexes are pelletted and discarded as 
insoluble factors. Also RD23B, an ubiquitin receptor that binds ubiquitinated proteins and delivers 
these proteins to the regulatory proteasomal particle 
(Dantuma et al., 2009)
 turned out to be downregulated. 
We can speculate this downregulation as a cellular attempt to regulate an augmented proteasomal 
activity. The picture emerging from our results is at the moment far from being clear. However, 
alteration in the level of cytosolic ubiquitinated proteins in DM2 cultures are consistent with a 
modified ubiquitin mediated degradative machinery. Alteration in the ubiquitin-protein conjugates 
has also been recently reported 
(Salisbury et al., 2009)
 although in that case an increase rather than 
decrease has been observed. However, differences in the experimental protocols (isolation of 
cytosolic proteins in the presence of 0.5% detergent in our case as compared to total extract as 
reported by 
(Salisbury et al., 2009)
 could justify the discordances. Alteration in the ubiquitin-mediated 
proteasomal system may impair the degradation machinery affecting protein stability. Although our 
present results do not allow to define if this is the case, very recent work  
(Huichalaf et al., 2009)
 has 
demonstrated reduction of the rate of protein translation in patients with myotonic dystrophy 2. An 
altered degradation machinery  in DM2  myotubes cultures it is not completely unforeseen. In fact, 
the ubiquitin-proteasome proteolytic system is involved in muscle wasting 
(Attaix et al., 2005,  Murton et al., 
2008)
 which is one of the features of dystrophic muscles. It is feasible that the altered splicing of 
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insulin receptor may affect insulin mediated signaling acting on the proteasomal degradation 
machinery. It is also possible that the alteration in the level of proteins involved in protein 
degradation may become an early biomarker for the wasting process.  The mitochondria is probably 
the most relevant compartment for which we found a significant reduction in the protein profile of 
DM2 cultures. The proteins identified belong to different biological processes required for the 
biogenesis and function of the mitochondria. Among the proteins we detected, two spots (possibly 
postranslationally modified proteins as reported by He et al., in 2001) were identified as  EFTu. For 
both of them we found a global reduction further confirmed by western blotting. EFTu is a nuclear 
encoded protein that plays a major role in mitochondrial translational machinery.  Mutation and/or  
reduction  of this protein  has been detected in infantile encephalopathy 
(Valente et al., 2007)
 with 
muscular hypotonia and degradation of motor skills. EFTu is a GTPase that participates in the 
formation of the ternary complex (EFTu:GTP:aminoacyl tRNA). The switch between an active 
(GTP-bound) and inactive (GDP-bound) forms requires the EFTs factor and the efficiency of 
mitochondrial translation is critically dependent on the relative ratios of these forms and other 
mitochondrial translation elongation factors. Interestingly our data points to a constant ratio 
between EFTu and EFTs in control cultures while the  relative reduction of EFTu in DM2 cultures 
is not associated with the reduction of EFTs level. As reported in fig. 13, in the DM2 cytosolic 
extracts the level of EFTs fluctuates, thus causing the Tu/Ts ratio to be highly variable. 
Interestingly, alterations in the EFTu/Ts ratio has been reported in patients with fatal hepatopathy 
(Coenen et al., 2004)
. Future experiments will allow to understand if the changes in EFTu depicted in 
DM2 cultures affect the mitochondrial translation efficiency. Among the mitochondrial proteins 
found altered in DM2 cultures, we detected a reduction of the mitochondrial  Heat Shock Protein 60 
and Glucose-Regulated Protein 75 (also referred to as Stress-70
 
Protein). These proteins participate 
in the mitochondrial translocation reaction of matrix-target precursor proteins and in protein folding 
within the mitochondrial matrix, assisting in the maintenance of mitochondrial proteome integrity 
(Rassow et al., 1999)
. Together these two proteins perform mitochondrial import, chaperoning and quality 
control functions in mitochondria.. We also depicted a reduced level of delta dienoyl-Co-A 
isomerase, a mitochondrial enzyme involved in beta oxidation of odd fatty acids. Therefore it is 
possible that folding, import processes, and metabolic processes necessary for the bioenergetic 
function of the mitochondria are altered. Interestingly, we found an increase of-
trimethylaminobutyraldehyde dehydrogenase, an enzyme involved in the biosynthesis of carnitine  
a mitochondrial carrier for fatty acid and this might be a compensatory response to the reduced 
level of some  mitochondrial proteins. In conclusion our functional proteome analysis suggests that 
other molecular functions and biological processes, in addition to spliceopaty, are affected in the 
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DM2 disease. The effects of CCTG repeat expansion extend therefore beyond spliceopathy to 
include a more general disturbance leading to changes, important for the physiological role of the 
muscular tissue. Further studies on the role of both mitochondria and the ubiquin-proteasomal 
machinery may lead to the development of new terapeutic approaches that can be useful to block or 
partially prevent muscle wasting in human DM2 patients. To this extent we evaluated Human DM 
fibroblasts as a model system for further investigations, directed to a better understanding of the 
Mitochondrial and Degradation-related problems potentially underlying the DM2 pathology. We 
produced a fibroblast bank from an average of 10 DM1, DM2 and control patients. Several 
cryotubes filled with cells were stored for future studies. Our preliminary data showed no 
correspondance between the degradation abnormalities displayed by DM2 myoblasts, and the 
fibroblasts degradative behaviour. In particular, while myoblasts from patients affected showed 
diminished amounts of Ubiquitin-protein conjugates in the basal condition, and a higher increase of 
the levels of these conjugates after MG-132 proteasomal inhibitor treatment, the fibroblasts did not. 
We are confident on the MYO-D adenoviral conversion to the muscular lineage of the fibroblasts in 
order to obtain a good model to study this feature. The use of fibroblast cultures to study possible 
mitochondrial issues is definitely more promising, since not only this patient’s cell type displays a 
different steady state of the membrane potential, but also shows a differential ability to respond to 
hydrogen peroxide mediated oxidative stress. A marked release of cytochrome c from the 
mitochondrial inner membrane is readily released in DM2 fibroblasts, at peroxide concentrations 
able to elicit a basal release from DM1 and control cells, suggesting a deep difference between the 
two pathologies, at the level of the mitochondrial involvement. 
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b
. ABSTRACT 
 
GSK3 beta, a potential target in Myotonic Dystrophy type 1.*** 
Differentiation of skeletal muscle depends at least in part on the formation of a multiprotein 
complex. Cyclin D3 is the only cyclin supporting growth arrest and differentiation. 
Hypophosphorylated pRb binds to Cyclin D3 protecting this protein against  GSK3beta degradative 
phosphorylation and promoting the formation a complex, capable to sequester Cdk4 and PCNA. 
This triggers the irreversibile exit from the cell cycle and promotes specific differentiative gene 
expression. The differentiation process is impaired in DM1 primary myoblasts. CUGBP1, is a 
multifunctional protein involved in splicing control in the nucleus, mRNA stability, and translation 
rate in the cytosol. While its level increases during normal myoblast differentiation, in DM1 cells it 
does not. Moreover, it fails to bind eIF2 and in turn is not able to promote translation initiation of 
important gene products involved in the differentiation process. Phosphorylation at different sites 
drives CUGBP1 to bind specific proteins and hence mRNAs targets. CyclinD3/cdk4 complex is 
responsible for the addition of a phosphate at CUGBP1 Ser-302 committing this protein to the 
differentiation task. In DM1 cells, CyclinD3 and Cdk4 do not increase their level and possibly do 
not phosphorylate CUGBP1.  
To better understand the relationship between DM1 CTG microsatellite amplification and the 
differentiatiation issues of the disease, and to asses whether or not the differentiation problem could 
be defined as early pathogenic event, we used CTG 914 inducible HeLa stable clones. With these 
cells we found that the expression of the amplification itself is sufficient to downregulate the level 
of Cyclin D3 and Cdk4, in both cytosol and nuclei. Moreover we used a trangenic mouse model 
expressing the CTG amplification to test if the mutation could also affect the levels of GSK3beta. 
We found a strong overexpression of GSK3beta in skeletal muscle, and of both mRNA and protein. 
This overexpression could be pivotal for the impairment of Cyclin D3 turnover and for the 
abnormal development of myotubes. Taken together, these data suggest a correlation between the 
expression of the CTG amplification and the impairment of the differentiation machinery in both 
cellular and animal models of the DM1 pathology. 
Keywords: Muscle differentiation, pRB, Cyclin D3, GSK3 beta, Myotonic Dystrophy type 1, CTG 
repeats.  
***This work was performed in the Laboratory of Professor Lubov Timchenko, at the Baylor College of Medicine, 
Houston, (TX) USA.  
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b
. INTRODUCTION 
2.1 Differentiation overview: 
Skeletal muscle differentiation involves terminal withdrawal from the cell cycle, induction of 
muscle-specific gene expression and fusion of myoblast into polynucleated myotubes. For the 
majority of the cell types, including myoblasts, proliferation and differentiation are mutually 
exclusive events. Muscle specific transcription factors, belonging to the MyoD family, are 
responsible for the initiation and the maintenance of the myogenic program.  Muscle regulatory 
factors (MRFs) are bHLH transcription factors. They promote differentiation by binding specific 
consensus sequence (E-box) at the regulatory regions of muscle-specific genes
1,2,3
.  For what 
concerns the induction of the cell cycle arrest, we know that MyoD induces transcription of  
Retinoblastoma (pRb), that can mediate the induction of transcription of the cell cycle inhibitor p21. 
Muscle differentiation is associated with induced expression of pRb
4
, and with enhanced nuclear 
affinity in its active hypophosphorylated state. 
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Rb is known to be inactivated by the Cyclin dependent kinases (Cdks) phosphorylation. These 
kinases act in conjunction with the Cyclins
5,6 
,which display a regulatory activity on the kinase and 
promote the progression of the cell cycle. The expression of the majority of the Cyclins is 
downregulated during terminal differentiation of muscle cells. This brings about the arrest of the 
cell cycle progression and the entry in a G1/G0 state. Only Cyclin D3 acts differently. Since its 
expression is induced during terminal differentiation.
7,8 
.  Cdks are negatively regulated by the Cdk. 
These inhibitors can bind either Cdks or Cyclin/Cdks complexes blocking their activity and 
blocking therefore the cell cycle. p21 is an important Cdk inhibitor which can also function as a 
direct DNA polymerase inihibitor by binding the Proliferating Cell Nuclear Antigen (PCNA)
9
. 
Cenciarelli et al.
10
 reported a direct involvement of the hormone-activated MyoD, , in the induction 
of Myogenin, p21, pRb, and Cyclin D3. They proposed a model in which MyoD activates target 
genes by two consequential molecular mechanisms, the first requiring p300 and the second 
requiring pRb. p300 is essential for the direct induction of MyoD itself, pRb, p21 and Cyclin D3 
which are referred to as early differentiation markers. pRb is required for Myogenin-mediated 
induction of late differentiation genes as well for the irreversible cell cycle arrest needed for the 
terminal differentiation
10
. 
With regard to Cyclin D3, Cenciarelli et al. reported that in differentiating C2C12 myoblasts not 
only that Cyclin D3 mRNA is induced, but also a stabilization of Cyclin D3 at the protein level 
occurs. Protein accumulation requires the function of pRb, since pRb
-/- 
cells induced to differenciate 
fail to accumulate Cyclin D3 protein, despite a normal induction of Cyclin D3 mRNA. The low 
level of Cyclin D3 in differentiating muscle cells lacking pRb is supported by the intrinsic 
instability of the protein, since the administration of proteasomal inhibitors increased the steady 
state levels of this Cyclin. In addition this data shed some light on the role of pRb in the protection 
of Cyclin D3 from the Ubiquitin-proteasome mediated degradation. But which is the pathway that 
controls the Cyclin D3 levels in myogenic cell lines? What about the mechanisms underlying the 
pRb protection toward Cyclin D3? To address these questions, De Santa et al
13
., worked to 
understand the rules governing the formation of the multiprotein complex in which the bulk of 
Cyclin D3 is pRb-associated. Their results suggest that Cyclin D3 acts as a bridging molecule, 
allowing pRb to sequester inactive Cdk4 complexes as well as PCNA into insoluble nuclear 
structures. They discovered the important role of GSK3beta, a multifunctional protein kinase, 
initially identified as a regulator in insulin-dependent glycogen synthesis. Over the last decade it 
turned out that GSK3beta is involved in a number of functions, including the regulation of cell fate 
(role in the Wnt and Hedgehog signalling pathways), signal transduction, protein synthesis, mitosis 
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and apoptosis
11
. Ubiquitin-mediated proteasomal degradation of Cyclin D3 is triggered by the 
phosphorylation of Cyclin D3 Thr-286, since replacement of Thr-286 with Alanine (T286A) 
markedly stabilized this protein, preventing it from polyubiquitination. Interestingly, GSK3beta is 
responsible for this phosphorylation at least in vitro
12
. Moreover the treatment of pRb negative 
myoblasts with LiCl a specific inhibitor of GSK3beta, resulted in Cyclin D3stabilization, and could 
further prolong the half-life also of Cyclin D3 in pRb 
+/+ 
myocites, indicating additive effects of 
pRb and GSK3beta inactivation on this stabilization
12
. GSK3 beta is normally active in cells, and is 
physiologically regulated through inibition of its activity in response to multiple signals
13
, the most 
of which are the insulin, and insulin-like growth factors. Insulin-like growth factors potentially 
stimulate muscle differentiation and skeletal muscle hypertrophy through the activation of the 
PI3K/Akt pathway
14
. Akt is a serine-threonine protein kinase that phosphorylates a number of 
substrates including GSK3beta which is in turn inactivated. It is worth mentioning that a classic 
clinical feature in both DM1 and DM2 patients is insulin resistance
15
.  Alternative splicing of the 
insulin receptor (IR) pre-mRNA is aberrantly regulated in DM1 skeletal muscle and exon 11 is 
preferentially excluded, resulting in predominant  expression of the insulin insensitive splice form, 
IR-A
16
.  
2.2 DM1 differentiative issues and role for CUGBP1 
It has been proposed that impaired differentiation of skeletal muscle is one of the critical events in 
DM1 muscle cells
24
. The expression of mutant DMPK mRNA with long CUG repeats, alters the 
physiological behaviour of CUGBP1
17,18
. This multifunctional RNA binding protein is involved in 
the regulation of  multiple RNA processing stages: from the cap-dependent and cap-indipendent 
translation, to RNA stability and splicing
19
. Investigations in mouse model of the DM1 pathology 
showed an overexpression of CUGBP1 leading to impairment of muscle development and 
differentiation
20
, Muscular Dystrophy, and Myotonia
21
. During differentiation the complex 
myogenin/E2/p300 binds to CUGBP1 promoter E-box, increasing its transcription
22
. Important 
target gene for CUGBP1 are p21, a Cdk inhibitor as described before, Myocyte enhance factor 2A 
(Mef2A), Insulin receptor and the Chloride ion channel. 
CUGBP1 is phosphorylated by different kinases and specific phosphorylation of this protein 
changes its RNA binding affinity toward different mRNAs: Akt phosphorylates  CUGBP1 at Ser-28 
and this particular posttranslational isoform of the protein shows a higher affinity for Cyc D1 
mRNA On the contrary, phosphorylation by Cyclin D3-Cdk4 increases the affinity of CUGBP1 for 
p21 and C/EBPbeta
23
. Studying protein-protein interactions, Salisbury et al.
23
 found that during 
myoblasts proliferation, CUGBP1 interacts with active Akt while, during differentiation, it binds to 
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Cyclin D3/Ckd4. Moreover, the phosphorylation by CyclinD3/Cdk4 increases the affinity of 
CUGBP1 for eIF2, a factor mediating translation initiation. All these data shed some light on the 
role of Cyclin D3 as one of the critical regulator of CUGBP1 activities in myotubes. A possible 
correlation between the lack of early muscle differentiation markers expression and low or 
indetectable levels of  Cyclin D3 in pRb
-/-
 myoblasts, is supported by the incorrect phosphorylation 
of CUGBP1 and hence the consequent inability to work properly during the differentiation process. 
In particular, proliferating DM1 cells show a much stronger CUGBP1/Akt interaction than that 
found in control cultures. Moreover, while normal differentiation of control myoblasts is 
characterized by increased levels of Cyclin D3 and of Cdk4, and a corresponding increase of 
CUGBP1/eIF2 complex formation, DM1 cells do not display such an increase. The lack of 
elevation of Cyclin D3 in DM1 cells seems to be a critical event leading to impaired myoblast 
fusion, since normalization of these levels corrects early step of differentiation
23
. 
2.3 GSK3beta implications in the Cyclin D3-CUGBP1-eIF2 pathway 
Studies performed in mice liver revealed a critical role for GSK3beta in the epigenetic regulation of 
the hepatocytes proliferation via reduction of Cyclin D3/Cdk4 complex. Cytoplasmic Cyclin 
D3/Cdk4 complex interacts with CUGBP1 triggering its phosphorylation at Ser-302, and this 
promotes its binding to eIF2
24
. The accumulation of Cyclin D3 in liver of old mice, which leads to a 
dramatic elevation of  the CUGBP1/eIF2 complex
25
, is accompanied by reduced levels of 
GSK3beta. This correlates with activation of Cdk4 and CUGBP1 hyperphosphorylation. On the 
contrary, in the liver of young mice GSK3beta phosphorylates Cyclin D3 at Ser-283 which causes 
its degradation via 26S proteasome. Interestingly, the GSK3beta pathway takes place not only in the 
liver, but also in lung, brain and adipose tissue. But which is the biological meaning of the binding 
between eIF2 and CUGBP1? This complex increases the translation of two proteins, C/EBPbeta 
and HDAC, involved in the epigenetic control of translation. These proteins work by repressing the 
translation of specific target genes among which GSK3beta itself
26
. In fact, the GSK3beta promoter 
contains three C/EBPbeta binding sites which are located in close proximity of the transcription 
initiation site. C/EBP/HDAC1 represses transcription by the deacetylation of the K9 residue of 
Histone H3 and subsequent trimethylation: the analysis of Histone H3 at the level of the GSK3beta 
promoter shows this pattern of repression.  
In this work we tried to clarify the relationship between the expression of the CTG-914 
amplification, and the deregulation of proteins such as Cyclin D3, pRb, Cdk4 and GSK3beta, 
participating in the differentiation process. We used stable clones of HeLa cells expressing the 
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amplification in an inducible manner, and showed how the CTG amplification by itself is sufficient 
to reduce the Cyclin D3 and Cdk4 levels in both cytosol and nuclei. We also found overexpression 
of GSK 3 beta both at the level of mRNA and protein, in muscles of a transgenic mouse model of 
DM1. These results can suggest a possible mechanism which could be responsible for the 
impairment of the differentation process in DM1. 
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b
. MATERIALS AND METHODS 
3.1 Cell Culture 
The double-stable HeLa cells expressing CUG-914 were grown in DMEM containing 10% tet-free 
FBS (Clontech Laboratories, Mountain View, CA, USA) suppemented with Geneticin and 
Hygromicin B to 80% density. Cytoplasmic and nuclear fractions were collected from cells in 100 
mm plates, either  without the additino of  DOX or maintained for 48 hours in medium containing 
DOX (500ng/ul). Expression of GFP and CUG-914 RNA was verified by fluorescente analysis and 
by northern blot. C2C12 myoblasts were cultured in F10 medium (Gibco), containing 15% FBS, 
5% defined complemented calf serum (Hyclone) and 1% penicillin/streptomycin, the myoblast 
growth medium was changed after two days. In order to promote differentiation, myoblasts were 
grown to 80% confluency, and at that point the growth medium was replaced with fusion medium, 
containing 2% Horse serum, 0,01M insulin in DMEM. The fusion medium was replaced every day. 
The cells were differentiated five days. 
3.2 Subcellular fractionation 
The HeLa double-stable clones were lysed in proper conditions to obtain two fractions: one fraction 
enriched in cytosolic/membrane proteins, and one in nuclear proteins. The cells, scraped and 
pelleted, were treated with an hypotonic buffer (10 mM Hepes pH 7.5, 0.5% NP-40, 10 mM KCl, 1 
mM EDTA, 1 mM DTT, additioned with proteases and phosphatases inhibitors). After 15 min of 
mild agitation, cells were centrifuged at 400X g at 4 °C. The supernatant was then centrifuged at 
15,000X g to clarify the extract and the supernatant, representing the cytosolic/membrane enriched 
fraction, was collected. The pellet obtained from the 400X g centrifugation was treated with an 
hypertonic buffer, (20 mM Tris–HCl pH 7.5, 0.6 M NaCl, 0.2 mM EDTA, 1.4 mM MgCl2 25% 
glycerol, and proteases and phosphatases inhibitors) with mild agitation for 15 min at 4 °C and then 
centrifuged at 80,000X g at 4 °C. The supernatant was collected, representing the nuclear enriched-
fraction. 
 3.3 HPLC 
Nuclear extracts of HeLa stable clones treated and untreated with DOX were subjected to size 
exclusion chromatography, on a SEC400 column,  precalibrated with molecular weight markers. 
The chromatography fractions (300 ul) were analyzed by western blot. 
3.4 Immunoprecipitation 
Immunoprecipitation was performed using e-Bioscience TrueBlot. Mouse IgG TrueBlot ULTRA is 
ideal for use in protocols involving immunoblotting of immunoprecipitated proteins. TrueBlot 
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preferentially detects the nonLreduced form of mouse IgG over the reduced, SDSLdenatured form of 
IgG. When the immunoprecipitate is fully reduced immediately prior to SDSLgel electrophoresis, 
reactivity of Mouse IgG TrueBlot ULTRA with the 55 kDa heavy chains and the 23 kDa light 
chains of the immunoprecipitating antibody is minimized thereby eliminating interference by the 
heavy and light chains of the immunoprecipitating antibody in IP/immunoblotting applications. 
500ug-1mg of total protein obtained from homogeneization of i) HeLa stable clones, treated and 
untreated with DOX,  ii) C2C12 myoblasts used as positive control, iii) Mice biopsies (muscle 
MIX) (buffer 50mM Tris-HCl pH 8.0, 150mM NaCl, 0,5-1% NP-40). 1-10 ug of  Cyclin D3 
antibody (Santacruz biotechnology, C-16 sc-182)  was used to immunoprecipitate Cyclin D3, while 
western blot was performed using anti pRb (Santacruz Biotechnology, C-2 sc-74562 1:600) 
3.5 Western blot analysis 
Western blot analysis were performed with cytoplasmic and nuclear proteins, as described 
previously, 20 to 80 ug of proteins were separated by gel electrophoresis, blotted on a 
nytrocellulose membrane, and and incubated with different antibodies. Polyclonal anti-Cyclin D3 
(sc182, C-16) 1:600; polyclonal anti-pRb, (sc50,C-15) 1:700; monoconal anti-GSK3alpha/beta 
(sc7291, 0011-A) 1:1000; polyclonal anti-Cdk4 (C-22, 1:750) polyclonal anti-alphaTubulin (H-300 
5546) 1:1000, were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Monoclonal anti-
betaActin antibodies (AC-15) were from Sigma-Aldrich (St.Louis, MO, USA) 
3.6 Semiquantitative RT-PCR 
RNA was extracted from transgenic mice muscle biopsies (200-CTG in the 3’UTR of (HSA) 
Human Skeletal Actin) gene, using TRIzol reagent, (Invitrogen). Total RNA was run to determine 
the degradation state, and the 28S and 18S ribosomal subunits were observed. RNA 
retrotranscription was performed using Taqman reverse transcription reagents kit (Applied 
Biosystems, Baranchburg, NJ) with 10 ng of starting RNA (1ul). The RT-PCR was performed at 
93°C, 57°C, 72°C for 20 cycles using 1,2 and 4 ul of c-DNA from the retrotranscribed total mRNA, 
and Red-MIX (Roche) PCR-buffer, on a total volume of 25 ul each tube. GSK3beta was analyzed 
with the specific primers whose sequence is: forward, 5’-TTCCTTTGGAATCTGCCATC-3’, 
reverse, 5’-TCAGTGCCTCCAAAGATCAA-3’. The GSK3beta production was normalized by the 
analysis of GAPDH expression with the following primers: forward,                                               
5’-AACTTTGGCATTGTGGAAGGGCTC-3’ and reverse,                                                                 
5’-TGGAAGAGTGGGAGTTGCTGTTGA-3’. 
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b
. RESULTS 
4.1 Expression of the CTG amplification in HeLa cells affects the expression level of the 
differentiation complex Cyclin D3/pRb/Cdk4 core components.               
Cyclin D3 and Cdk4 are consistently expressed in both cytosolic and nuclear fractions of HeLa 
cells, C2C12, Cos7 cells (data not shown) while pRb is highly expressed only in the nuclear 
fractions of these cell types. In this study we used HeLa CTG-914 double stable clones which 
transcribe the CTG amplification in an inducible fashion, after somministration of Dox 
(Doxycyclin) according to TET-ON technology. It is worth noting that the CTG amplification lays 
in a different position at the level of the DNA, compared to the human mutation, and this give the 
possibility to study the effect of this simple mutation, without the interference of the positional 
implications of it. The CTG amplification is under the control of a CMV promoter.  
 
 
 
 
Figure.2: 
Schematic representation of the CUG-914, CUG-25 cassette in HeLa stable clones. rtTA: Tetracyclin controlled 
transactivator. 
We decided to investigate whether or not the differentiation complex components could be 
influenced at the level of protein expression, by the induction of the CTG-914 transcription, in this 
HeLa double stable clones. Surprisingly we found a strong decrease of Cyclin D3 level following 
CTG-914 Dox-induction, indicating a tight correlation between the mutation and the physiological 
behavior of this protein both in the cytoplasmic environment and in the nucleus. It is interesting to 
appreciate that the major decrease in the levels of Cyclin D3 affects the nuclear fraction, while a 
minor decrease is evident in the cytosol. As we expected, from the Cyclin D3 total extract asset 
after DOX treatment, we detected an average decrease with respect to untreated cell culture extract. 
This result provide a further proof of the statistical robustness of the data presented, which anyhow 
display a p<0,001. We can speculate a functional implication of the different fold increase affecting 
the Cyclin D3 levels in the different subcellular fractions taken into consideration, since diverse 
localozations of these proteins correspond to different functions and roles as described under 
Introduction. 
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Figure. 3: Panels A, B, C show respectively immunoreactive bands of Cyclin D3 in Cytosolic, Total and Nuclear 
extracts of HeLa double stable clones expressing the CTG amplification and untreated with Doxicyclin. Panel D shows 
the average intensity level of Cyclin D3 after normalization with the internal control. 4 different cell extracts (treated 
and untreated with Dox)  were evaluated for the Cyclin D3 levels (p<0,001). 
Since the Cyclin D3/pRb/Cdk4 complex which is present in C2C12 cells, promotes the withdrawl 
from the cell cycle and the induction of early muscle differentiation markers, and involves a 
protective role of pRb toward Cyclin D3, we decided to estimate the levels of Retinoblastoma  
 
 
 
 
 
 
Figure. 4:  Immunoblot analysis showing the pRb levels dependence on the CTG amplification expression (panel A) in 
HeLa double stable clones. Average intensity levels of pRb respectively with and without the Dox treatment, after Beta 
Actin normalization are shown in panel B, 3 cellular enriched nuclear fractions either treated or untreated for the 
expression of the CTG-914 amplification were used (p<0,001) 
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protein and whether this level could be perturbed by the CTG expression on HeLa stable clones. We 
found an effect on the pRb levels, which showed a consistent overexpression following 
amplification expression. 
We proceeded by analysing the levels of CDK4, the third protein known to play a role in 
conjunction with cyclin D3 in the phosphorylation of CUGBP1, at Ser-302. CDK4 committs it to 
accomplish its roles in the differentiation process of the muscle cells. It was very intringuing to find 
out a very similar trend with respect to Cyclin D3. As one can observe in figure 5, while the 
cytosolic levels of this protein underwent a slight decrease tendency following the translation of the 
CTG amplification, the nuclear enriched proteic fraction showed a dramatic decrease of the 
expression of Cdk4 when the mutant RNA was present in the cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure. 5: Panels A, B, C show respectively immunoreactive bands of Cdk4 in Cytosolic, Total and Nuclear extracts of 
HeLa double stable clones expressing the CTG amplification and untreated with Doxicyclin. Panel D shows the average 
intensity level of Cdk4 after normalization with the internal control. 3 different cell extracts (treated and untreated with 
Dox) were evaluated for the Cdk4 levels (p<0,05; nuclear variation. p<0,1; total extract variation. Tendency to decrease 
for the cytosolic variation). 
The last protein we were interested into was GSK3beta. Since we found downregulation of Cyclin 
D3 following the expression of the CTG amplification in HeLa stable clones, we thought that an 
increased activity or level of GSK3beta, could be responsible for the cyclin D3 reduction via 
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phosphorylation of its Thr-286, and consequent ubiquitination and 26S proteasome digestion. As it 
is easy to observe in Figure. 6, at least in cells, we did not find an increase in GSK3 beta with 
statistical significance, since in the total extract, and in the cytosolic extract, we observed a 
substantial invariance and only a slight tendency to GSK3beta upregulation in the cytosolic 
compartment, while in the nuclear environment this proteic species displays a tendency to 
downregulation.  
 
 
 
 
 
 
 
 
 
 
 
Figure. 6: Panels A, B, C show respectively immunoreactive bands of GSK3beta in Cytosolic, Total and Nuclear 
extracts of HeLa double stable clones expressing the CTG amplification and untreated with Doxicyclin. Panel D shows 
the average intensity level of GSK3beta after normalization with the internal control. 3 different cell extracts (treated 
and untreated with Dox) were evaluated for the Cdk4 levels (We couldn’t obtain a strong statistical significance of this 
levels variation, we would better talk about a tendency of the trends we describe). 
 
In conclusion the cellular model used in these studies, turned out to be important. It gave us the 
chance to identify a correlation between the expression of the mutant-toxic RNA and the levels of 
some proteins, like Cyclin D3, Cdk4, and pRb. This also proves that HeLa cells are able to 
ricapitulate some of the most important biochemical and cellular aspects of the DM1 pathology.  
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4.2 The interaction between pRb and Cyclin D3 is undetectable in immortalized HeLa cells as well 
as in double stable clones expressing CTG-914 
The CTG amplification itself causes protein expression changes of the components of the 
differentiation complex. We decided therefore to evaluate the capability ofthe Cyclin D3-Rb 
complex to form in order to understand whether the expression of the CTG-914 amplification could 
also interfere with this process. We decided to undertake two different solutions to address this 
issue: i) we performed HPLC (size exclusion chromatography) on the nuclear extract of  HeLa 
cells, both expressing the CTG amplification and controls, ii) we co-immunoprecipitated Cyc D3 
and Rb in a reciprocal manner. The multiprotein complex which forms during muscle cells 
differentiation, as described by De Santa et al. (2007), includes pRb, Cyclin D3, Cdk4, PCNA and 
represents a high molecular weight complex. The idea about the use of HPLC, was to identify those 
high molecular weight protein fractions characterized by the presence of both Cyclin D3 and pRb, 
as well as to evaluate whether the expression of CTG repeats could affect the association of the two 
proteins at the level of the HMW fractions. Unfortunately this approach turned out to be 
unsuccessful in assessing the differences in the complex formation. This was be due to either 
experimental problems, like the high salt concentration needed in order to obtain the nuclear 
proteins affecting the protein-protein interactions, or cellular characteristics of the immortalized cell  
 
 
 
 
 
 
 
 
Figure. 7:   Immunoblot analysis of the chromatographic fractions with antibodies against Rb, Cyclin D3 and beta 
Actin. Cyclin D3 is undetectable in the high molecular weight fractions of HeLa cells (nuclear extract) either expressing 
or not expressing the CTG repeats.   
lines. Normally this type of cells cannot form complexes involved in the differentiation tasks, 
because one of the two interacting proteins, Rb, is an oncosuppressorwhich is probably inactivated, 
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or  at least hyperphosphorylated (inactive isoform) in tumor cells. The second approach we sought 
to use to isolate the complex behaviour was the Co-immunoprecipitation (Co-IP) between the two 
proteins of interest, Cyclin D3 and Retinoblastoma protein. 
 
 
 
Figure. 8:  Immunoblot analysis of  the input, not bound and immunoprecipitate of  HeLa cells treated and untreated 
with DOX in order to express the CTG amplification. Cyclin D3 antibody was used to precipitate the Cyclin while 
antibody against Rb was used to immunodecorate the nitrocellulose filter. No Rb bands are detectable in the 
immunoprecipitate lanes. In the last lane 25 ug of proteins extracted from mouse gastro muscle were used as a positive 
control. 
As one can observe in figure 8, Cyclin D3 did not pull-down pRb. This result represents a second 
proof that the complex did not form in this particular cellular system. Defining a cellular model that 
could help in the comprehending how the differentiative mechanisms are affected by the CTG 
amplification, could be a very important task. It should be taken into account that understanding the 
relation between the mutation and the differentiative implications of it, could shed some light on a 
very important issue of the pathology, and on critical pathways important for a terapeutic approach. 
We decided so far to evaluate the behaviour of Cyclin D3/pRb complex in C2C12 myoblasts, which 
are able to differentiate, and in turn to form myotubes. As De Santa at al
13
. already proved. We  
evaluated a consistent increase of the expression of pRb, and Cyclin D3, during the differentiation 
process with respect to proliferating myoblasts (Fig. 9) 
 
 
 
 
 
Figure. 9: Immunoblot analysis showing the increase in the levels of Cyclin D3 (panel A) and pRb (panel B) after 5 
days of differentiation, total protein extracts of C2C12 cells were analyzed. 
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Figure. 10: Immunoblot analysis showing the impossibility to co-immunoprecipitate Cyclin D3 and pRb even in C2C12 
cells. Cyclin D3 was immunoprecipitated and the precipitate was screened using the anti-pRb antibody. 
Anyway once again it turned out to be impossible to evidence an interaction between these proteins 
in this cellular system. In the cell types which differentiate into myotubes we could observe the 
differetially phosphorylated pRb isoforms. The higher molecular weight ones represent 
hyperphosphorylated pRb, while the lower at ! 102 KDa, represents the hypophosphorylated pRb. 
(Fig. 10) None of them showed its co-immunoprecipitated counterpart. A further experiment we 
planned to perform was the co-transfection of  Cyclin D3 and pRb in the HeLa stable clones 
expressing the CTG amplification, and the analysis of the complex in these conditions compared to 
controls, since we hypotesized that the interaction using larger amounts of proteins might become 
detectable. 
4.3 In vivo evidentiation of the Cyclin D3 pRb complex formation. 
What supported the hypotesis about the lack or the difficulties in revealing the complex formation 
in HeLa cells and in C2C12 cells but not in animal models, was not only the positive control of 
figure 8, which shows that Rb protein is present in the Cyc D3 immunoprecipitate, but also the 
experiment performed on Gastro muscle from WT and transgenic CTG mice. For these reasons we 
decided to switch to a different model, a mouse model available in the lab, characterized by the 
constitutive expression of 250-CTG repeats mapping at the level of the skeletal Actin. Once again 
the mutation at the level of the DNA was not localized in the correct position in which we find it in 
the human DM1 pathology (3’UTR of the DMPK gene) and this aspect is important since the 
underlying idea is to demonstrate a role for the CTG amplification tout court, in the pathogenesis of 
the DM1, and not linked to a particular position and to its interference with the flanking genes 
mapping near the amplification. We used anti-pRb antibody  in order to co-immunoprecipitate Cyc 
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D3, and this time we obtained the first insight about the possibility of a less efficient complex 
formation in the presence of the CTG amplification (figure 11). 
 
 
 
 
 
 
 
 
Figure. 11: Immunoblot analysis of  the input, not bound and immunoprecipitate of Gastro muscle proteic extract 
obtained from WT and CTG transgenic mice. Immunoprecipitation: Anti-pRb antibody, Western Blot: Anti-CycD3 
antibody (panel A). The differential intensity of Cyclin D3 bands show a tendency to reduction in the ability of pRb to 
pull-down Cyclin D3 in the gastro muscle of trangenic CTG expressing mouse (panel B). 
4.4 Overexpression of GSK3 beta in the CTG-250 mouse model. 
The cellular model we used so far gave us some indications connecting CTG amplification and the 
level of relevant proteins, as we showed, but it did not allow us to study neither the hypothetical 
implications of the CTG expression on the differentiative complex formation, nor the  kinetic of the 
interactions between the molecular actors so far described. Moreover, we couldn’t support our 
hypothesis about the GSK3beta toxic gain of function. On the contrary using the animal model, we 
demonstrated on the one hand that the differentiative complex forms, on the other we raise the 
possibility of an altered complex formation in vivo. We further decided to evaluate the levels of 
GSK3beta in a total protein extract obtained from a heterogeneous muscle biopsy that we called 
“Muscle Mix”. This decision was taken to perform a randomization of the muscle used, since 
depending on the particular muscle of the animal, it is possible to evaluate different expression of 
specific gene products. The muscles included on this “mix” were primarily the diafragm, the neck 
muscles, and the abdominal muscles. We planned to compare of the GSK3beta levels of the CTG 
transgenic mice, versus the control WT mice, and eventually get into the particular muscles once 
obtained preliminary results on the “Muscle Mix” biopsies. This experiments represented the 
second part of our research plan: the evaluation of GSK3beta levels in transgenic mouse was done 
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in order to propose a preliminar hypothesis about the differential Cyclin D3-pRb pull down 
property of CTG-250 mice. Our results indicate a strong overexpression of GSK3beta gene product 
in the CTG-250 transgenic mice compared to controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 12: Immunoblot analysis representing the immunoreactive bands of GSK3beta in a total proteic extract of 
control mice (lanes 1,3) and CTG-250 transgenic mice (lanes 2,4) (Panel A). In panel B, average densitometric intensity 
of GSK3beta after internal control normalization. We compared 4 total extracts from control mouse to 4 total extracts 
from CTG-250 trangenic mouse. (p<0,05). 
GSK3beta is known to be inactivated by AKT kinase following insulin or insulin like growt factor 
cell stimulation. A particular feature of DM is insulin-resistance, due to the uncorrect splicing of the 
insulin receptor (IR). Furthermore, the inactivating phosphorylation of Ser-9 by AKT creates a 
docking site for E3-Ubiquitin ligase, hence GSK3beta is degraded by the 26S proteasome. We 
decided to evaluate whether or not this increase could be related to an altered turnover of 
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GSK3beta, or eventually could play a role also the transcription process. We extracted RNA from 
“Muscle Mix” biopsies and after retrotranscription, we performed RT-PCR. In figure 13 we provide 
proof of the total RNA integrity after extraction with TRIzol reagent, as showed by the presence of 
28S and 18S bands of the ribosomal RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 13: RNA gel electrophoresis analysis to asess the quality of the total RNA obtained by TRIzol extraction. 
 
Our results show that changes in mRNA levels are consistent with the increase in the protein levels  
of GSK3beta in transgenic CTG-250 mice. In figure 14 we provide PCR evidence of the  difference 
in mRNA expression, anyway we are still not able to assess whether the transcription rate could be 
faster, or this kind of transgenic mouse could be chatacterized by different stability of the 
GSK3beta mRNA. A corresponding mRNA and protein level involvement in patient’s biopsies 
needs to be evaluated, and could represent an important feature both as a biomarker of the DM1 
disease and a therapeutic target of the pathology. 
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Figure. 14:  PCR analysis of retrotranscribed c-DNA from control and CTG-200 trangenic mice (Panel A). PCR 
products of180 bp and 400 bp are specific for GSK3beta and GAPDH respectively. GAPDH transcript was used to 
normalize the cDNA concentration. 2 ul of DNA preparation were used in order to evidence the GSK3beta amplicon, 1 
ul was used to visualize GAPDH fragment. GSK3beta primers: forward, 5’-TTCCTTTGGAATCTGCCATC-3’, 
reverse, 5’-TCAGTGCCTCCAAAGATCAA-3’. GAPDH primers: forward, 5’-
AACTTTGGCATTGTGGAAGGGCTC-3’ and reverse,                                                                 5’-
TGGAAGAGTGGGAGTTGCTGTTGA-3’. We performed only 25 cycles of PCR to avoid GAPDH signal saturation. 
In panel B: average intensity levels of the GSK3beta PCR product after normalization on GAPDH, we performed 2 
PCR reactions using the same retrotranscribed c-DNA from control and CTG-250 mouse once the PCR conditions were 
set. 
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b
. DISCUSSION 
Human Myotonic Dystrophy type 1 affects the capability of myoblasts obtained from patients 
biopsies to differentiate properly in vitro. In these cells the differentiation process, the phenomenon 
of myoblasts approaching, and the fusion of the plasma membranes leading to the formation of the 
multinucleated muscle fibers is poorly efficient, and the same can be said for the protein aspects of 
the differentiation process. Cells lack the burst of some proteic species, such as CUGBP1 which, as 
we already mentioned, plays a pivotal role in the process. Also they lack the Ciclin D3 and Cdk4 
level increase, that is relevant to trigger and control the phosphorylated state of CUGBP1 at serine-
302. The aim underlying the study of the differentiation issues in the Myotonic Distrophy type 1 is 
easy to guess i.e. correcting the mechanisms which menage the proper differentiation of the DM1 
muscle cells will be important on a therapeutic base. Symptoms like atrofia and muscle weakness. 
Defects in the differentiation process could cause an impairment of continuous renewal and 
substitution of damaged fibers, underlying the physiological behavior of skeletal muscles. 
We already know from C2C12 immortalized mouse myoblasts studies that differentiation is 
mediated by the formation of a multiprotein complex made up of Cyclin D3/pRb/Cdk4/PCNA. We 
also know that its functions are manifold and span from Cyclin D3 protection against intrinsic 
instability, sequestration of cell cycle progression promoters, phosphorylation of proteins such as 
CUGBP1. We also know that CUGBP1 triggers translation of p21 mRNA, and in conjunction with 
eIF2, actively translates C/EBPbeta and HDAC1 mRNAs, pushing the cells to the silentiation of 
transcription of factors involved in cell proliferation. We already know the role of GSK3beta kinase 
in the in vitro phosphorylation of Cyclin D3 which may tigger its nuclear export and degradation. 
Moreover Cyclin D3 levels could be restored in C2C12 myoblasts lacking pRb, (protective role on 
Cyclin D3) by using GSK3beta specific inhibitor LiCl, or MG-132 26S proteasomal inhibitor. At 
this point some questions still remain open: I) Is it possible to define a role for the differentiative 
complex Cyclin D3/pRb/Cdk4 in the impairment of the  DM1 cells differentiation process? II) If so, 
is the impairment of the formation of the complex and/or of the levels of its members, an early 
event depending uniquely on the CTG repeats amplification expression, or this could be triggered 
by a complex interaction between different molecular aspects of the pathology? III) Is it possible to 
think of a tossic gain of function of GSK3beta, depending on a particular post-translational 
modification, and/or an overexpression of it depending on an augmented transcription, or mRNA 
stabilization, or translational rates, or impaired degradation? IV) Could we hypothesize a 
malfunction of the differentiation complex core formation (Cyclin D3/pRb)? V) Can we define a 
mechanism by which, if so, this differentiation complex cannot form properly, like a connection 
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between a peculiar phosphorylation state or post-translational modification of Cyclin D3 and/or 
pRb and the expression of the CTG repeats amplification which could affect the binding between 
them? 
In this study we intended to trace a possible correlation between the expression of a particular DNA 
mutation, a CTG microsatellite amplification, causing the Myotonic Dystrophy type 1, and the 
pathologic behaviour of the multiprotein complex, involved in a number of differentiative 
functions. We needed to respond to a cause-effect issue, working in a simplified environment. We 
chose HeLa cells, expressing the mutation under CMV-TET-ON inducible promoter. In this cellular 
model we could demonstrate a direct correlation between the CTG-914 repeats RNA, and important 
variation in the expressive profile of the core components of this Cyclin D3/pRb/Cdk4 
differentiation complex. In particular we detected an important downregulation of Cyclin D3, after 
the Doxicyclin administration to the culture medium. This level decrease characterizes both the 
nuclear and the cytosolic compartment, but is more prominent in the nucleus. It is of course also 
detectable at the level of the total proteic extract with a error threshold lower than 0,001. Cyclin D3 
is the only Cyclin promoting, in appropriate conditions, the exit from the Cell Cycle and the 
commitment differentiation. Once the Myoblasts are prompted to form muscle fibers by serum 
deprivation, the physiological differentiation burst depends on the expression of early and late 
muscle differentiation markers, such as Myogenin, Myosin Heavy Chain, and p21
12
, an important 
Cdk inhibitor, able to block the cell cycle progression. The same was shown for Cdk4, which is the 
cognate Cyclin Dependent Kinase of Cyclin D3. During differentiation Cyclin D3 and Cdk4 were 
shown to act together in the phosphorylation of important molecular targets
23
, such as CUGBP1, a 
pivotal protein in the pathogenesis of the DM disease. A parallel decreased level of them is 
intringuing, since it turn out to be easy, to speculate about a common mechanism of augmented 
degradation eventually mediated by 26S proteasome, or at least a common involvement of  their 
levels change. The decreasing trend of Cdk4 follows with a certain fedelity the Cyclin D3 one. 
Interestingly we found a decrease of Cdk4 level mainly in the nucleus, but a reduction also in the 
cytoplasm was observed. It will be interesting to further evaluate a time course of the combined 
level variations after Dox administration, in order to strictly couple these events. Our results 
indicated a strong correlation between the CTG triplets transcription, resulting in the formation of 
ribonuclear inclusions (data not shown), and the pronounced decrease of Cyclin D3 and Cdk4. This 
evidence shed some light on the role of the amplification itself, and not on the particolar position of 
it at the level of the DNA, in order to affect the levels differentiation proteins. It would be very 
interesting as well, to investigate whether or not after CTG repeats expression in HeLa cells, 
CUGBP1 could decrease its phosphorylation levels at Ser-302, taking into account that this 
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arrangement pushes differentiation against proliferation, and hence this mechanism could be 
inhibited in this highly proliferating cellular model. In the determination of the levels of pRb, the 
“protector” of Cyclin D3 from degradation, it was kind of weird to note that pRb was modulated as 
well by the expression of CUG repeats RNA. We found pRb upregulated. It is difficult to speculate 
on the reason for that, since differentiation problems are eventually due to its decrease. One 
possibility is that pRb working as a oncosuppressor increases its levels to suppress the toxic CTG 
expression in the nucleus, even if a role as a oncosuppressor is unlikely in HeLa cell lines. An 
alternative explaination is a compensatory attempt to counteract the decrease of Cyclin D3. 
GSK3beta was the last protein we checked for the expression level. In HeLa CTG-914 we could not 
obtain a clear result (statistically significant) about the relation between GSK3beta levels and CTG 
repeats expression. The levels were substantially invariant, apart for a tendency to decrease for the 
nuclear fraction, and a tendency to increase in the cytosolic one. An analysis on how the CTG 
repeats could interfere with the GSK3beta levels could have been very important with the aim to 
provide a hypothetical mechansm about the decrease of Cyclin D3, since GSK3 mediates the 
degradation of it.  
We know (data not shown) that HeLa CTG-914, as well as DM myoblasts from patients, express 
the fetal splice variant of the insulin receptor. This isoform, IR-A (without exon 11) is less sensitive 
to the insulin signal with respect to the physiologically expressed IR-B, and this in turn provide 
evidence of the insulin resistance characteristic of the DM. Since the insulin signaling activates Akt, 
via PI3K phosphorylation, and Akt is responsible for GSK3beta inactivation by adding a phosphate 
to Ser-9, and hence for its proteasomal degradation, we hypothesized a failure in this process, 
entailing augmented cellular levels of GSK3beta. However, our data obtained in HeLa cells do not 
give us the possibility to conclude whether or not such a mechanism could underlie the decrease of 
Cyclin D3/Cdk4. 
In order to address our further questions, involving the possibility of impairment on the 
differentiation complex formation, first we needed to demonstrate the existence of the complex in 
our cellular model based on HeLa CTG-914 double stable clones and C2C12 cells as a positive 
control. At least in C2C12, we have been confident on this possibility since De Santa et al.
12 
demonstrated in vitro a competition between pRb ad GSK3beta binding to Cyclin D3. 
Unfortunately, while we were addressing this task, we encountered the first problem: in both 
C2C12 myoblasts, myotubes, and in HeLa stable clones we were working on, it turned out to be 
impossibile to evidence a co-immunoprecipitation between endogenous proteins. To all intents and 
purposes we must underline De Santa et al. were able to evidence an in vitro co-
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immunoprecipitation of Cyclin D3, pRb, and GSK3beta, in Sf9 insect cells, only after having used a 
huge amount of the Baculovirus expressed proteins. We tried to modulate the amount of proteins 
used, the antibody concentration, the concentration of detergents in the lysis buffer, but we were 
unable to obtain such a co-immunoprecipitation in these cell types. Another approach was to co-
transfect the cells in order to make them express higher levels of the three proteins of interest, or 
alternatively, to use patients myoblasts and myotubes, since both C2C12 and HeLa are 
immortalized cells, characterized by certain peculiarities with respect to primary cultures. It is  
important to remark that we evidenced a co-immunoprecipitation of pRb-Cyclin D3 in vivo, using a 
protein extract from gastro muscle of adult WT and CTG transgenic mice, attesting for the first time 
an effective existence of  this complex in mammals skeletal muscle. This transgenic mouse shows 
atrophy, small myofibers, centralized nuclei, and a reduced walking and running ability at the Rota-
Road test on a time basis (data not shown). Although further confirmations are needed, preliminary 
results show a differential capability of pRb to pull down Cyclin D3, although it is far too early to 
assess whether it depends on a differential binding affinity or simply on the reduced level of Cyclin 
D3 that could be less available for the binding to pRb. We conclude that, if on the one hand, CTG-
914 HeLa double stable clone, was important to establish a causal dependence between the 
expression of the CTG repeats mutation and the change in the expression levels of Cyclin D3, 
Cdk4, and pRb, on the other hand, its potential help in addressing part of the still open questions we 
placed was poor. Indeed we were not able to demonstrate either the differentiative complex 
formation, involving Cyclin D3 and pRb, or the mechanism potentially involving GSK3beta in the 
Cyclin D3 level decrease. On the contrary, we evaluated as a powerful tool the CTG-250 transgenic 
mouse model. In future we plan to define whether the differential Cyclin D3-pRb binding 
characterizing this animal model could be a matter of a change in the affinity between them, or 
could depend on a differential availability of one or both of them. 
As we said, the power of in vivo system, involving CTG-250 transgenic mice was likely to be 
greater: for this reason we decided to evaluate the GSK3beta levels, with the attempt to propose an 
explaination for the differential cabability of pRb to co-immunoprecipitate Cyclin D3. We found a 
marked and clear increase of the GSK3beta levels in muscle biopsies of CTG-250 expressing 
transgenic mice, compared to controls, and RT-PCR analysis shed also light on a transcript increase 
in this in vivo model. A lot of work still needs to be done: we need to extend of the number of the 
mice to be evaluated on this aspect, find the typology of muscles in which the overexpression is 
higher, and evaluate in the human myoblasts and biopsies of DM1 patients a confirmation of this 
results. It will be thereafter foundamental to define whether the treatment with LiCl, the specific 
GSK3beta inhibitor could recover the differentiation issues of the DM1 human myoblasts. It is clear 
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that this work could be important and propaedeutical to a possible terapeutic approach aimed to 
correct the differentiative defects involving Myotonic Distrophy type 1.   
I wish to add that this report was carried out in the frame of a bigger project on myopathies which 
is going on in the laboratory of Professor Lubov Timchenko. Hela CTG-914/GFP double stable 
clones were obtained, at the Baylor College of Medicine, Houston, Texas, in order to study the 
early molecular and cellular events which follow the induction of the amplification of the 
micrisatellite triplet CTG. In particular they are studying the RNA foci kinetics of formation and the 
interference of this mutation with the cellular process of protein translation. They hypothesized that 
at least in part, the CTG amplification itself, (and the CCTG amplification in DM2)is responsible 
for the pathogenesis of the disease, independently on the position this mutation has in the DNA. It is 
important to declare that in the Human pathology Myotonic Dystrophy, the position of the 
amplification, (3’UTR of DMPK gene in DM1, and first intron of Znf9 in DM2) hardly matters, but 
on the one hand, part of the molecular and cellular problems characterizing the DM belongs to the 
interference with the correct expression of  the genes we just enumerated, while on the other hand a 
number of symptoms and feature of Myotonic Dystrophy, could be related on the characteristics of 
the ribonuclear amplifications, its secondary structure, and the property to sequester a number of 
proteic species. This two overlapping mechanisms need to be separated in order to deeply 
understand their implications in the pathogenesis of the disease. Ribonuclear inclusions form 
following the translation of the CTG repeats, and CCTG repeats, in both Human, and cellular 
models of the disease. With the HeLa double stable clones it could be possible not only to study the 
kinetics of formation of the RNA foci, immediately after the expression induction of CTG repeats, 
but also to obtain information about their degradation as soon as the Doxicyclin is withdrawn from 
the culture medium. In the same way, different molecules could be tested in order to assess possible 
properties in promoting foci degradation, and hence, on a therapeutic point of view.  With the same 
aim, a transgenic mouse model was obtained to better define the implications of the unique CTG 
amplification on the pathogenesis of a Dystrophyc disease in mammals, and to assess whether 
muscle weakness, myotonia, and muscular atrophy, could raise independently on the position of the 
mutation. 
 
 
 
 
 74 
6
b
. BIBLIOGRAPHY 
1. Buckingham, M. 1992 Making muscle in mammals, Trends Genet. 8:144-148 
 
2. Emerson, C.P.1993. Skeletal Myogenesis: genetics and embryologyto the fore. Curr. Opin. 
Genet. Dev. 3:265-274. 
 
3. Olson,E.N. et al. 1994. bHLH factors in muscle development:dead line and commitments: 
what to leave in and what to leave out. Genes dDev. 8:1-8. 
 
4. Endo, T. and S. Goto. 1992. Retinoblastoma gene product Rb accumulates during 
myogenic differentiation, and is deinduced by the SV40 large T antigen. J. Biochem. 
112:427-430. 
 
5. Morgan D.O. 1995. Principles of Cdk regulation. Nature 374:131-134. 
 
6. Norbury, C. and P. Nurse. 1992. Animal cell cycles and their control. Annu. Rev. 
Biochem. 61:441-470. 
 
7. Kiess, M. et al. 1995. Expression of the positive regulator of cell cycle progression Cyclin 
D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene. 10: 
159-166. 
 
8. Rao, S. S.,  and D.S. Kotz, 1995. Positive and negative regulation of D-type Cyclin  
9. expressionin in skeletal myoblast by basic fibroblast growth factor and transforming growth 
factor beta, a role of Cyclin D1 for myoblast differentiation. J. Biol. Chem. 270. 4093-4100 
 
10. Waga, S. et al. 1994. The p21 inhibitor od cyclin dependent kinases controls DNA 
replication by interaction with PCNA. Nature 369:574-578. 
 
11. Cenciarelli et al. 1999. Critical role played by Cyclin D3 in the MyoD-Mediated arrest of 
the cell cycle, during Myoblast differentiation. Mol. Cell. Biol. 19:5203-5217 
 
12. J.E. Forde and T.C. Dale. 2007. Glycogen synthase kinase 3: a key regulator of cellular 
fate. Cell. Mol. Life Sci. 64: 1930-1944. 
 
13. De Santa et al. 2007. pRb dependent Cyclin D3 stabilization is required for myogenic 
differentiation. Mol. Cell. Biol. 27:7248-7265. 
 
14. Doble, B. et al. 2003. GSK3: triks of the trade for a multi-tasking kinase. J. Cell. Sci. 
116:1175-1186. 
 
15. Coolican, S. A. 1997. The mitogenic and myogenic actions of insuline like-growth factors 
utilize different signaling pathways. J. Biol. Chem. 272:6653-6662. 
 
16. Moxley RT. et al. 1980. Muscle insulin resistance in Myotonic Dystrophy: effect of 
supraphysiologic insulinization. Neurology. 30:1077–83.   
 
17. Day, J.W. and Ranum L. 2005. RNA pathogenesis of the Myotonic Dystrophies. 
Neuromuscular Dis. 15:5-16. 
 
18. Timchenko, LT. et al. Novel protein with binding specificity for DNA CTG repeats and 
RNA CUG repeats: implication for Myotonic Dystrophy. Hum. Mol. Gen. 1996. 5:115-121. 
 
19. Timchenko, NA. et al. Overexpression of CUG triplet repeat binding protein, CUGBP1, 
inhibits myogenesis. J. Biol. Chem. 2004. 279:13129-13139. 
 
 75 
20. Philips, AV. et al. 1998. Distruption of Splicing regulated by CUG-binding protein in 
Myotonic Dystrophy. Science. 280:737-741. 
 
21. Ho, TH. et al. 2005. Transgenic mice expressing CUG-BP1 reproduce splicing mis-
regulation by observed in Myotonic Dystrophy. Hum. Mol. Gen. 14:1539-1547 
 
22. Mahadevan, MS. et al. 2006. Reversibile model of RNA toxicity and cardiac conduction 
defects in Myotonic Dystrophy. Nat. Genet. 38:1066-1070. 
 
23. Huichalaf, CH. et al. 2007. Regulation of the promoter of CUG triplet binding protein 
CUGBP1, during myogenesis. Gene. 396:391-402 
 
24. Salisbury, E. et al. 2008. Ectopic expression of Cyclin D3 corrects differentiation of DM1 
myoblasts through activation of CUG-binding protein, CUGBP1. 314:2266-2278. 
 
25. Timchenko, NA. et al. 2005. CUG triplet repeat binding protein CUGBP1, increases 
translation of C/EBP isoform, LIP, by interacting with the alpha and beta subunits of eIF2. 
J. Biol. Chem. 280:20549-20557. 
 
26. Timchenko, LT. et al. 2006. Age specific CUGBP1-eIF2 complex increases translation of 
C/EBP in old liver. J. Biol. Chem. 281:32806-32819 
 
27. Jin, J. et al. 2009. The age associated decline of GSK3beta plays a critical role in the 
inibition of liver rigeneration. Mol. Cell. Biol . 29:3867-3880 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 81 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
